{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:39:10Z","timestamp":1794609550241,"version":"4.9.1"},"reference-count":495,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL141174, HL152973, HL158659"],"award-info":[{"award-number":["HL141174, HL152973, HL158659"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02982-0","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:02:39Z","timestamp":1788217359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6868-7927","authenticated-orcid":false,"given":"Zicheng","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-7900","authenticated-orcid":false,"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5043-2936","authenticated-orcid":false,"given":"Jonathan","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravya","family":"Aragam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orshina","family":"Dawd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Belthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-8277","authenticated-orcid":false,"given":"Tanya V.","family":"Kalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-2660","authenticated-orcid":false,"given":"Vladimir V.","family":"Kalinichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2982_CR1","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41591-023-02327-2","volume":"29","author":"L Sikkema","year":"2023","unstructured":"Sikkema, L. et al. An integrated cell atlas of the lung in health and disease. Nat. Med. 29, 1563\u20131577 (2023).","journal-title":"Nat. Med."},{"key":"2982_CR2","doi-asserted-by":"publisher","first-page":"eabd9149","DOI":"10.1126\/science.abd9149","volume":"373","author":"CC Wang","year":"2021","unstructured":"Wang, C. C. et al. Airborne transmission of respiratory viruses. Science 373, eabd9149 (2021).","journal-title":"Science"},{"key":"2982_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101\u2013124 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2982_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T. et al. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 6, 53 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/v15030698","volume":"15","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom, K. Viral vectors in gene therapy: where do we stand in 2023? Viruses 15, 698 (2023).","journal-title":"Viruses"},{"key":"2982_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan, D. et al. Nanomedicine in cancer therapy. Signal Transduct. Target Ther. 8, 293 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2492236","volume":"17","author":"A Sepp","year":"2025","unstructured":"Sepp, A. et al. The physiological limits of bispecific monoclonal antibody tissue targeting specificity. MAbs 17, 2492236 (2025).","journal-title":"MAbs"},{"key":"2982_CR8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","volume":"102","author":"DB Hill","year":"2022","unstructured":"Hill, D. B., Button, B., Rubinstein, M. & Boucher, R. C. Physiology and pathophysiology of human airway mucus. Physiol. Rev. 102, 1757\u20131836 (2022).","journal-title":"Physiol. Rev."},{"key":"2982_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120761","volume":"271","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis. Biomaterials 271, 120761 (2021).","journal-title":"Biomaterials"},{"key":"2982_CR10","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1021\/acs.molpharmaceut.1c00491","volume":"18","author":"S Pramanik","year":"2021","unstructured":"Pramanik, S. et al. Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases. Mol. Pharm. 18, 3671\u20133718 (2021).","journal-title":"Mol. Pharm."},{"key":"2982_CR11","unstructured":"World Health Organization. Global Tuberculosis Report 2024 https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024 (2024)."},{"key":"2982_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nri.2017.69","volume":"17","author":"AM Cadena","year":"2017","unstructured":"Cadena, A. M., Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 17, 691\u2013702 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"2982_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj7790","volume":"13","author":"F D\u2019Agnillo","year":"2021","unstructured":"D\u2019Agnillo, F. et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. 13, eabj7790 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2982_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1164\/rccm.202109-2150OC","volume":"206","author":"JA Villalba","year":"2022","unstructured":"Villalba, J. A. et al. Vasculopathy and increased vascular congestion in fatal COVID-19 and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 206, 857\u2013873 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR15","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson, S. A., Smith, B. M., Bafadhel, M. & Putcha, N. Chronic obstructive pulmonary disease. Lancet 399, 2227\u20132242 (2022).","journal-title":"Lancet"},{"key":"2982_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-17686-9","volume":"24","author":"N Al Wachami","year":"2024","unstructured":"Al Wachami, N. et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health 24, 297 (2024).","journal-title":"BMC Public Health"},{"key":"2982_CR17","doi-asserted-by":"publisher","first-page":"230009","DOI":"10.1183\/16000617.0009-2023","volume":"32","author":"JCS Holtjer","year":"2023","unstructured":"Holtjer, J. C. S. et al. Identifying risk factors for COPD and adult-onset asthma: an umbrella review. Eur. Respir. Rev. 32, 230009 (2023).","journal-title":"Eur. Respir. Rev."},{"key":"2982_CR18","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn, J. S. Cystic fibrosis. Lancet 388, 2519\u20132531 (2016).","journal-title":"Lancet"},{"key":"2982_CR19","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong, T. & Ramsey, B. W. Cystic fibrosis: a review. JAMA 329, 1859\u20131871 (2023).","journal-title":"JAMA"},{"key":"2982_CR20","doi-asserted-by":"publisher","first-page":"9260","DOI":"10.3390\/ijms25179260","volume":"25","author":"L de la Bastida-Casero","year":"2024","unstructured":"de la Bastida-Casero, L., Garcia-Leon, B., Tura-Ceide, O. & Oliver, E. The Relevance of the endothelium in cardiopulmonary disorders. Int. J. Mol. Sci. 25, 9260 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(24)00295-9","volume":"13","author":"GBD 2021 Pulmonary Arterial Hypertension Collaborators","year":"2025","unstructured":"GBD 2021 Pulmonary Arterial Hypertension Collaborators Global, regional, and national burden of pulmonary arterial hypertension, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Respir. Med. 13, 69\u201379 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2982_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/CIRCRESAHA.122.321554","volume":"132","author":"I Cuthbertson","year":"2023","unstructured":"Cuthbertson, I., Morrell, N. W. & Caruso, P. BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension. Circ. Res. 132, 109\u2013126 (2023).","journal-title":"Circ. Res."},{"key":"2982_CR23","doi-asserted-by":"publisher","first-page":"e177926","DOI":"10.1172\/jci.insight.177926","volume":"9","author":"MM Zhu","year":"2024","unstructured":"Zhu, M. M. et al. GCN2 kinase activation mediates pulmonary vascular remodeling and pulmonary arterial hypertension. JCI Insight 9, e177926 (2024).","journal-title":"JCI Insight"},{"key":"2982_CR24","doi-asserted-by":"publisher","first-page":"1801965","DOI":"10.1183\/13993003.01965-2018","volume":"54","author":"C Galambos","year":"2019","unstructured":"Galambos, C. et al. Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. Eur. Respir. J. 54, 1801965 (2019).","journal-title":"Eur. Respir. J."},{"key":"2982_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fbioe.2019.00172","volume":"7","author":"D Wu","year":"2019","unstructured":"Wu, D. & Birukov, K. Endothelial cell mechano-metabolomic coupling to disease states in the lung microvasculature. Front. Bioeng. Biotechnol. 7, 172 (2019).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"2982_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-16","volume":"3","author":"L Fregonese","year":"2008","unstructured":"Fregonese, L. & Stolk, J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J. Rare Dis. 3, 16 (2008).","journal-title":"Orphanet J. Rare Dis."},{"key":"2982_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/TACG.S257511","volume":"14","author":"S Seixas","year":"2021","unstructured":"Seixas, S. & Marques, P. I. Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum. Appl Clin. Genet. 14, 173\u2013194 (2021).","journal-title":"Appl Clin. Genet."},{"key":"2982_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/cells13110974","volume":"13","author":"KA Despotes","year":"2024","unstructured":"Despotes, K. A., Zariwala, M. A., Davis, S. D. & Ferkol, T. W. Primary ciliary dyskinesia: a clinical review. Cells 13, 974 (2024).","journal-title":"Cells"},{"key":"2982_CR29","doi-asserted-by":"crossref","unstructured":"Wee, W. B. et al. Primary ciliary dyskinesia. Pediatrics 153, e2023063064 (2024).","DOI":"10.1542\/peds.2023-063064"},{"key":"2982_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1164\/rccm.202312-2249SO","volume":"210","author":"E Melen","year":"2024","unstructured":"Melen, E. et al. Asthma inception: epidemiologic risk factors and natural history across the life course. Am. J. Respir. Crit. Care Med. 210, 737\u2013754 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR31","doi-asserted-by":"publisher","first-page":"210112","DOI":"10.1183\/16000617.0112-2021","volume":"31","author":"M Aghapour","year":"2022","unstructured":"Aghapour, M. et al. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD. Eur. Respir. Rev. 31, 210112 (2022).","journal-title":"Eur. Respir. Rev."},{"key":"2982_CR32","doi-asserted-by":"publisher","first-page":"100995","DOI":"10.1016\/j.mam.2021.100995","volume":"85","author":"ZI Komlosi","year":"2022","unstructured":"Komlosi, Z. I. et al. Cellular and molecular mechanisms of allergic asthma. Mol. Asp. Med. 85, 100995 (2022).","journal-title":"Mol. Asp. Med."},{"key":"2982_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A. et al. Lung cancer. Lancet 398, 535\u2013554 (2021).","journal-title":"Lancet"},{"key":"2982_CR34","doi-asserted-by":"publisher","first-page":"210045","DOI":"10.1183\/16000617.0045-2021","volume":"30","author":"PR Benusiglio","year":"2021","unstructured":"Benusiglio, P. R. et al. Lung cancer is also a hereditary disease. Eur. Respir. Rev. 30, 210045 (2021).","journal-title":"Eur. Respir. Rev."},{"key":"2982_CR35","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1183\/13993003.00359-2016","volume":"48","author":"J Malhotra","year":"2016","unstructured":"Malhotra, J. et al. Risk factors for lung cancer worldwide. Eur. Respir. J. 48, 889\u2013902 (2016).","journal-title":"Eur. Respir. J."},{"key":"2982_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1165\/rcmb.2020-0373PS","volume":"64","author":"A Pardo","year":"2021","unstructured":"Pardo, A. & Selman, M. The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 64, 163\u2013172 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1165\/rcmb.2024-0372TR","volume":"72","author":"SY Shin","year":"2025","unstructured":"Shin, S. Y. et al. From epithelium to therapy: transitional cells in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 72, 472\u2013483 (2025).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38177-2","volume":"14","author":"F Bian","year":"2023","unstructured":"Bian, F. et al. Lung endothelial cells regulate pulmonary fibrosis through FOXF1\/R-Ras signaling. Nat. Commun. 14, 2560 (2023).","journal-title":"Nat. Commun."},{"key":"2982_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss, B. J., Ryter, S. W. & Rosas, I. O. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 17, 515\u2013546 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"2982_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijheh.2020.113516","volume":"227","author":"RA Etzel","year":"2020","unstructured":"Etzel, R. A. The special vulnerability of children. Int. J. Hyg. Environ. Health 227, 113516 (2020).","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"2982_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1164\/rccm.201010-1697CI","volume":"184","author":"NB Bishop","year":"2011","unstructured":"Bishop, N. B., Stankiewicz, P. & Steinhorn, R. H. Alveolar capillary dysplasia. Am. J. Respir. Crit. Care Med. 184, 172\u2013179 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR42","doi-asserted-by":"publisher","first-page":"n1974","DOI":"10.1136\/bmj.n1974","volume":"375","author":"M Gilfillan","year":"2021","unstructured":"Gilfillan, M., Bhandari, A. & Bhandari, V. Diagnosis and management of bronchopulmonary dysplasia. BMJ 375, n1974 (2021).","journal-title":"BMJ"},{"key":"2982_CR43","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/thorax-2022-219482","volume":"77","author":"A Gie","year":"2022","unstructured":"Gie, A. & Toelen, J. Chronic neonatal lung disease: time to look beyond the alveolus. Thorax 77, 1161\u20131162 (2022).","journal-title":"Thorax"},{"key":"2982_CR44","doi-asserted-by":"publisher","first-page":"1112859","DOI":"10.3389\/fonc.2023.1112859","volume":"13","author":"J Donovan","year":"2023","unstructured":"Donovan, J. et al. Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1. Front. Oncol. 13, 1112859 (2023).","journal-title":"Front. Oncol."},{"key":"2982_CR45","doi-asserted-by":"publisher","first-page":"eadr8382","DOI":"10.1126\/science.adr8382","volume":"389","author":"JR Willis","year":"2025","unstructured":"Willis, J. R. et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 389, eadr8382 (2025).","journal-title":"Science"},{"key":"2982_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41551-022-00975-2","volume":"7","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging. Nat. Biomed. Eng. 7, 221\u2013235 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2982_CR47","doi-asserted-by":"publisher","first-page":"20210089","DOI":"10.1002\/EXP.20210089","volume":"1","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y., Zhang, Z., Pan, Z. & Liu, Y. Advanced bioactive nanomaterials for biomedical applications. Exploration 1, 20210089 (2021).","journal-title":"Exploration"},{"key":"2982_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202203890","volume":"35","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Hollow nanomaterials in advanced drug delivery systems: from single- to multiple shells. Adv. Mater. 35, e2203890 (2023).","journal-title":"Adv. Mater."},{"key":"2982_CR49","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41565-025-01903-6","volume":"20","author":"B Bussin","year":"2025","unstructured":"Bussin, B. et al. Discovering nanoparticle corona ligands for liver macrophage capture. Nat. Nanotechnol. 20, 914\u2013925 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR50","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1021\/acs.chemrev.1c00644","volume":"122","author":"B Zheng","year":"2022","unstructured":"Zheng, B. et al. Rare-earth doping in nanostructured inorganic materials. Chem. Rev. 122, 5519\u20135603 (2022).","journal-title":"Chem. Rev."},{"key":"2982_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52908-z","volume":"15","author":"D Fu","year":"2024","unstructured":"Fu, D. et al. Self-assembling nanoparticle engineered from the ferritinophagy complex as a rabies virus vaccine candidate. Nat. Commun. 15, 8601 (2024).","journal-title":"Nat. Commun."},{"key":"2982_CR52","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.7150\/thno.40805","volume":"10","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy. Theranostics 10, 3793\u20133815 (2020).","journal-title":"Theranostics"},{"key":"2982_CR53","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/nano13030574","volume":"13","author":"TM Joseph","year":"2023","unstructured":"Joseph, T. M. et al. Nanoparticles: taking a unique position in medicine. Nanomaterials 13, 574 (2023).","journal-title":"Nanomaterials"},{"key":"2982_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201906539","volume":"33","author":"M Jeon","year":"2021","unstructured":"Jeon, M., Halbert, M. V., Stephen, Z. R. & Zhang, M. Iron oxide nanoparticles as T(1) contrast agents for magnetic resonance imaging: fundamentals, challenges, applications, and prospectives. Adv. Mater. 33, e1906539 (2021).","journal-title":"Adv. Mater."},{"key":"2982_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.actbio.2019.11.027","volume":"102","author":"D Zhi","year":"2020","unstructured":"Zhi, D. et al. Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy. Acta Biomater. 102, 13\u201334 (2020).","journal-title":"Acta Biomater."},{"key":"2982_CR56","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.3390\/cancers13215275","volume":"13","author":"Z Deng","year":"2021","unstructured":"Deng, Z. et al. Dual targeting with cell surface electrical charge and folic acid via superparamagnetic Fe(3)O(4)@Cu(2-x)S for photothermal cancer cell killing. Cancers 13, 5275\u20135275 (2021).","journal-title":"Cancers"},{"key":"2982_CR57","doi-asserted-by":"publisher","first-page":"15471","DOI":"10.1021\/acsnano.1c03886","volume":"15","author":"TC Wareing","year":"2021","unstructured":"Wareing, T. C., Gentile, P. & Phan, A. N. Biomass-based carbon dots: current development and future perspectives. ACS Nano. 15, 15471\u201315501 (2021).","journal-title":"ACS Nano."},{"key":"2982_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejpb.2021.05.021","volume":"166","author":"Z Li","year":"2021","unstructured":"Li, Z., Perkins, W. & Cipolla, D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow(R) Technology. Eur. J. Pharm. Biopharm. 166, 10\u201318 (2021).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2982_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"X Li","year":"2024","unstructured":"Li, X. et al. Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct. Target Ther. 9, 1 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR60","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","volume":"5","author":"S Kalepu","year":"2015","unstructured":"Kalepu, S. & Nekkanti, V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm. Sin. B. 5, 442\u2013453 (2015).","journal-title":"Acta Pharm. Sin. B."},{"key":"2982_CR61","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cplu.202000496","volume":"85","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Development of high-drug-loading nanoparticles. Chempluschem 85, 2143\u20132157 (2020).","journal-title":"Chempluschem"},{"key":"2982_CR62","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach, M. A. et al. Polymeric nanoparticles for drug delivery. Chem. Rev. 124, 5505\u20135616 (2024).","journal-title":"Chem. Rev."},{"key":"2982_CR63","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7150\/thno.16357","volume":"7","author":"S Sun","year":"2017","unstructured":"Sun, S. et al. Targeting and regulating of an oncogene via nanovector delivery of MicroRNA using patient-derived xenografts. Theranostics 7, 677\u2013693 (2017).","journal-title":"Theranostics"},{"key":"2982_CR64","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/pharmaceutics13070950","volume":"13","author":"K Trzeciak","year":"2021","unstructured":"Trzeciak, K., Chotera-Ouda, A., Bak, S. II & Potrzebowski, M. J. Mesoporous silica particles as drug delivery systems-the state of the art in loading methods and the recent progress in analytical techniques for monitoring these processes. Pharmaceutics 13, 950 (2021).","journal-title":"Pharmaceutics"},{"key":"2982_CR65","doi-asserted-by":"publisher","first-page":"11527","DOI":"10.1021\/acs.chemrev.0c00997","volume":"121","author":"R Kumar","year":"2021","unstructured":"Kumar, R. et al. Polymeric delivery of therapeutic nucleic acids. Chem. Rev. 121, 11527\u201311652 (2021).","journal-title":"Chem. Rev."},{"key":"2982_CR66","doi-asserted-by":"crossref","unstructured":"Mendes, B. B. et al. Nanodelivery of nucleic acids. Nat. Rev. Methods Primers 2, 24 (2022).","DOI":"10.1038\/s43586-022-00104-y"},{"key":"2982_CR67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1039\/D3CS00194F","volume":"53","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity. Chem. Soc. Rev. 53, 317\u2013360 (2024).","journal-title":"Chem. Soc. Rev."},{"key":"2982_CR68","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1039\/D0CS00617C","volume":"49","author":"R Micura","year":"2020","unstructured":"Micura, R. & Hobartner, C. Fundamental studies of functional nucleic acids: aptamers, riboswitches, ribozymes and DNAzymes. Chem. Soc. Rev. 49, 7331\u20137353 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"2982_CR69","doi-asserted-by":"publisher","first-page":"e2001812","DOI":"10.1002\/adhm.202001812","volume":"10","author":"W Ho","year":"2021","unstructured":"Ho, W. et al. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv. Health. Mater. 10, e2001812 (2021).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 55, 2\u201312 (2022).","journal-title":"Acc. Chem. Res."},{"key":"2982_CR71","doi-asserted-by":"publisher","first-page":"114962","DOI":"10.1016\/j.addr.2023.114962","volume":"200","author":"S Puri","year":"2023","unstructured":"Puri, S. et al. Evolution of nanomedicine formulations for targeted delivery and controlled release. Adv. Drug Deliv. Rev. 200, 114962 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01790-w","volume":"21","author":"K Zhu","year":"2023","unstructured":"Zhu, K. et al. Berberin sustained-release nanoparticles were enriched in infarcted rat myocardium and resolved inflammation. J. Nanobiotechnol. 21, 33 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"2982_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12249-023-02502-1","volume":"24","author":"R Mahar","year":"2023","unstructured":"Mahar, R. et al. Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech. 24, 39 (2023).","journal-title":"AAPS PharmSciTech."},{"key":"2982_CR74","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.crtox.2022.100101","volume":"4","author":"JY Liu","year":"2023","unstructured":"Liu, J. Y. & Sayes, C. M. Lung surfactant as a biophysical assay for inhalation toxicology. Curr. Res. Toxicol. 4, 100101 (2023).","journal-title":"Curr. Res. Toxicol."},{"key":"2982_CR75","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1021\/acsnano.3c01452","volume":"17","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Molecularly stimuli-responsive self-assembled peptide nanoparticles for targeted imaging and therapy. ACS Nano. 17, 8004\u20138025 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR76","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acs.biomac.1c01691","volume":"23","author":"BHJ Gowda","year":"2022","unstructured":"Gowda, B. H. J. et al. Stimuli-responsive microneedles as a transdermal drug delivery system: a demand-supply strategy. Biomacromolecules 23, 1519\u20131544 (2022).","journal-title":"Biomacromolecules"},{"key":"2982_CR77","doi-asserted-by":"publisher","first-page":"e2000690","DOI":"10.1002\/adhm.202000690","volume":"10","author":"ZT Rosenkrans","year":"2021","unstructured":"Rosenkrans, Z. T., Ferreira, C. A., Ni, D. & Cai, W. Internally responsive nanomaterials for activatable multimodal imaging of cancer. Adv. Health. Mater. 10, e2000690 (2021).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR78","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/acsabm.2c00002","volume":"5","author":"MI Khan","year":"2022","unstructured":"Khan, M. I. et al. Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review. ACS Appl. Bio Mater. 5, 971\u20131012 (2022).","journal-title":"ACS Appl. Bio Mater."},{"key":"2982_CR79","doi-asserted-by":"publisher","first-page":"e2103444","DOI":"10.1002\/advs.202103444","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy. Adv. Sci. 9, e2103444 (2022).","journal-title":"Adv. Sci."},{"key":"2982_CR80","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.nanolett.1c03089","volume":"21","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. GSH-responsive nanoprodrug to inhibit glycolysis and alleviate immunosuppression for cancer therapy. Nano Lett. 21, 7862\u20137869 (2021).","journal-title":"Nano Lett."},{"key":"2982_CR81","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. Smart nanoparticles for cancer therapy. Signal Transduct. Target Ther. 8, 418 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR82","first-page":"44","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nanomicro Lett. 15, 44 (2023).","journal-title":"Nanomicro Lett."},{"key":"2982_CR83","doi-asserted-by":"publisher","first-page":"e2004721","DOI":"10.1002\/advs.202004721","volume":"8","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. A novel stimuli-responsive injectable antibacterial hydrogel to achieve synergetic photothermal\/gene-targeted therapy towards uveal melanoma. Adv. Sci. 8, e2004721 (2021).","journal-title":"Adv. Sci."},{"key":"2982_CR84","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2147\/IJN.S248987","volume":"15","author":"A Kasinski","year":"2020","unstructured":"Kasinski, A., Zielinska-Pisklak, M., Oledzka, E. & Sobczak, M. Smart hydrogels\u2014synthetic stimuli-responsive antitumor drug release systems. Int. J. Nanomed. 15, 4541\u20134572 (2020).","journal-title":"Int. J. Nanomed."},{"key":"2982_CR85","doi-asserted-by":"publisher","first-page":"20210023","DOI":"10.1002\/EXP.20210023","volume":"1","author":"L Tu","year":"2021","unstructured":"Tu, L. et al. Ultrasound-controlled drug release and drug activation for cancer therapy. Exploration. 1, 20210023 (2021).","journal-title":"Exploration."},{"key":"2982_CR86","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu, D. et al. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct. Target Ther. 8, 217 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR87","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1021\/acs.accounts.8b00292","volume":"51","author":"J Mosquera","year":"2018","unstructured":"Mosquera, J., Garcia, I. & Liz-Marzan, L. M. Cellular uptake of nanoparticles versus small molecules: a matter of size. Acc. Chem. Res. 51, 2305\u20132313 (2018).","journal-title":"Acc. Chem. Res."},{"key":"2982_CR88","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1513\/pats.200409-049TA","volume":"1","author":"JS Patton","year":"2004","unstructured":"Patton, J. S., Fishburn, C. S. & Weers, J. G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1, 338\u2013344 (2004).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"2982_CR89","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1089\/jamp.2010.0836","volume":"23","author":"JS Patton","year":"2010","unstructured":"Patton, J. S. et al. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J. Aerosol. Med. Pulm. Drug Deliv. 23, S71\u201387 (2010).","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"2982_CR90","doi-asserted-by":"publisher","first-page":"e2300319","DOI":"10.1002\/adhm.202300319","volume":"12","author":"TB Gandek","year":"2023","unstructured":"Gandek, T. B., van der Koog, L. & Nagelkerke, A. A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles. Adv. Health. Mater. 12, e2300319 (2023).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1021\/acs.accounts.1c00560","volume":"55","author":"D Pei","year":"2022","unstructured":"Pei, D. How do biomolecules cross the cell membrane? Acc. Chem. Res. 55, 309\u2013318 (2022).","journal-title":"Acc. Chem. Res."},{"key":"2982_CR92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2982_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1978","volume":"16","author":"S Wu","year":"2024","unstructured":"Wu, S., Lin, L., Shi, L. & Liu, S. An overview of lipid constituents in lipid nanoparticle mRNA delivery systems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 16, e1978 (2024).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"2982_CR94","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1039\/D0CS01414A","volume":"51","author":"E Linnane","year":"2022","unstructured":"Linnane, E. et al. The uptake of metal-organic frameworks: a journey into the cell. Chem. Soc. Rev. 51, 6065\u20136086 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"2982_CR95","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1039\/D3TB00322A","volume":"11","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. A computational study of the influence of nanoparticle shape on clathrin-mediated endocytosis. J. Mater. Chem. B. 11, 6319\u20136334 (2023).","journal-title":"J. Mater. Chem. B."},{"key":"2982_CR96","doi-asserted-by":"publisher","first-page":"14465","DOI":"10.1021\/acsnano.1c04001","volume":"15","author":"S E","year":"2021","unstructured":"E, S. et al. Tunable organelle imaging by rational design of carbon dots and utilization of uptake pathways. ACS Nano. 15, 14465\u201314474 (2021).","journal-title":"ACS Nano."},{"key":"2982_CR97","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/D0CS01127D","volume":"50","author":"M Sousa de Almeida","year":"2021","unstructured":"Sousa de Almeida, M. et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397\u20135434 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"2982_CR98","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","volume":"16","author":"JJ Rennick","year":"2021","unstructured":"Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266\u2013276 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR99","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/nn304439f","volume":"7","author":"H Herd","year":"2013","unstructured":"Herd, H. et al. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano. 7, 1961\u20131973 (2013).","journal-title":"ACS Nano."},{"key":"2982_CR100","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1021\/acsnano.5b03184","volume":"9","author":"S Zhang","year":"2015","unstructured":"Zhang, S., Gao, H. & Bao, G. Physical principles of nanoparticle cellular endocytosis. ACS Nano. 9, 8655\u20138671 (2015).","journal-title":"ACS Nano."},{"key":"2982_CR101","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nnano.2016.160","volume":"12","author":"E Hinde","year":"2017","unstructured":"Hinde, E. et al. Pair correlation microscopy reveals the role of nanoparticle shape in intracellular transport and site of drug release. Nat. Nanotechnol. 12, 81\u201389 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201910566","volume":"30","author":"W He","year":"2020","unstructured":"He, W. et al. Nanocarrier-mediated cytosolic delivery of biopharmaceuticals. Adv. Funct. Mater. 30, 1910566 (2020).","journal-title":"Adv. Funct. Mater."},{"key":"2982_CR103","doi-asserted-by":"publisher","first-page":"21398","DOI":"10.1039\/D4NR02408G","volume":"16","author":"AM Thamizhchelvan","year":"2024","unstructured":"Thamizhchelvan, A. M. et al. Shape-dependent cellular uptake of iron oxide nanorods: mechanisms of endocytosis and implications on cell labeling and cellular delivery. Nanoscale 16, 21398\u201321415 (2024).","journal-title":"Nanoscale"},{"key":"2982_CR104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2301067120","volume":"120","author":"L Zheng","year":"2023","unstructured":"Zheng, L., Bandara, S. R., Tan, Z. & Leal, C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc. Natl. Acad. Sci. USA 120, e2301067120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2982_CR105","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biomaterials.2018.02.052","volume":"166","author":"E Wonder","year":"2018","unstructured":"Wonder, E. et al. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo. Biomaterials 166, 52\u201363 (2018).","journal-title":"Biomaterials"},{"key":"2982_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.822","volume":"12","author":"M Zhou","year":"2022","unstructured":"Zhou, M. et al. The role of cell-penetrating peptides in potential anti-cancer therapy. Clin. Transl. Med. 12, e822 (2022).","journal-title":"Clin. Transl. Med."},{"key":"2982_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300236","volume":"18","author":"A Gori","year":"2023","unstructured":"Gori, A. et al. Cell penetrating peptides: classification, mechanisms, methods of study, and applications. ChemMedChem 18, e202300236 (2023).","journal-title":"ChemMedChem"},{"key":"2982_CR108","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/acs.molpharmaceut.3c01167","volume":"21","author":"M Pirhaghi","year":"2024","unstructured":"Pirhaghi, M. et al. Cell-penetrating peptides: promising therapeutics and drug-delivery systems for neurodegenerative diseases. Mol. Pharm. 21, 2097\u20132117 (2024).","journal-title":"Mol. Pharm."},{"key":"2982_CR109","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1021\/acs.bioconjchem.8b00778","volume":"30","author":"D Pei","year":"2019","unstructured":"Pei, D. & Buyanova, M. Overcoming endosomal entrapment in drug delivery. Bioconjug Chem. 30, 273\u2013283 (2019).","journal-title":"Bioconjug Chem."},{"key":"2982_CR110","doi-asserted-by":"publisher","DOI":"10.34133\/research.0148","volume":"6","author":"C Qiu","year":"2023","unstructured":"Qiu, C. et al. Advanced strategies for overcoming endosomal\/lysosomal barrier in nanodrug delivery. Research 6, 0148 (2023).","journal-title":"Research"},{"key":"2982_CR111","doi-asserted-by":"publisher","first-page":"e2104511118","DOI":"10.1073\/pnas.2104511118","volume":"118","author":"J Lee","year":"2021","unstructured":"Lee, J. et al. DNA-inspired nanomaterials for enhanced endosomal escape. Proc. Natl. Acad. Sci. USA 118, e2104511118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2982_CR112","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1039\/D4MH01781A","volume":"12","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Ukwattage, V., Xiong, Y. & Such, G. K. Advancing endosomal escape of polymeric nanoparticles: towards improved intracellular delivery. Mater. Horiz. 12, 3622\u20133632 (2025).","journal-title":"Mater. Horiz."},{"key":"2982_CR113","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","volume":"29","author":"R Bajracharya","year":"2022","unstructured":"Bajracharya, R. et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv. 29, 1959\u20131970 (2022).","journal-title":"Drug Deliv."},{"key":"2982_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202310781","volume":"20","author":"D Bi","year":"2024","unstructured":"Bi, D. et al. Deconvolving passive and active targeting of liposomes bearing LDL receptor binding peptides using the zebrafish embryo model. Small 20, e2310781 (2024).","journal-title":"Small"},{"key":"2982_CR115","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-101320-123742","volume":"40","author":"ML Matsumoto","year":"2022","unstructured":"Matsumoto, M. L. Molecular mechanisms of multimeric assembly of IgM and IgA. Annu Rev. Immunol. 40, 221\u2013247 (2022).","journal-title":"Annu Rev. Immunol."},{"key":"2982_CR116","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","volume":"320","author":"AC Marques","year":"2020","unstructured":"Marques, A. C., Costa, P. J., Velho, S. & Amaral, M. H. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J. Control Release 320, 180\u2013200 (2020).","journal-title":"J. Control Release"},{"key":"2982_CR117","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/pharmaceutics12090802","volume":"12","author":"A Juan","year":"2020","unstructured":"Juan, A. et al. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharmaceutics 12, 802 (2020).","journal-title":"Pharmaceutics"},{"key":"2982_CR118","doi-asserted-by":"publisher","first-page":"eabg2873","DOI":"10.1126\/sciadv.abg2873","volume":"7","author":"A Kanthe","year":"2021","unstructured":"Kanthe, A. et al. No ordinary proteins: sdsorption and molecular orientation of monoclonal antibodies. Sci. Adv. 7, eabg2873 (2021).","journal-title":"Sci. Adv."},{"key":"2982_CR119","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sbsr.2016.04.002","volume":"9","author":"MH Jazayeri","year":"2016","unstructured":"Jazayeri, M. H. et al. Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sens. Bio-Sens. Res. 9, 17\u201322 (2016).","journal-title":"Sens. Bio-Sens. Res."},{"key":"2982_CR120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40580-021-00274-7","volume":"8","author":"NK Lee","year":"2021","unstructured":"Lee, N. K. et al. Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities. Nano Converg. 8, 24 (2021).","journal-title":"Nano Converg."},{"key":"2982_CR121","doi-asserted-by":"publisher","first-page":"9816","DOI":"10.1039\/D0NR08191D","volume":"13","author":"M Bruckner","year":"2021","unstructured":"Bruckner, M., Simon, J., Landfester, K. & Mailander, V. The conjugation strategy affects antibody orientation and targeting properties of nanocarriers. Nanoscale 13, 9816\u20139824 (2021).","journal-title":"Nanoscale"},{"key":"2982_CR122","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.3390\/ijms21176018","volume":"21","author":"A Juan","year":"2020","unstructured":"Juan, A. et al. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment. Int. J. Mol. Sci. 21, 6018 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR123","doi-asserted-by":"publisher","first-page":"7638","DOI":"10.1021\/acs.chemrev.0c00920","volume":"121","author":"AK Agrahari","year":"2021","unstructured":"Agrahari, A. K. et al. Cu(I)-catalyzed click chemistry in glycoscience and their diverse applications. Chem. Rev. 121, 7638\u20137956 (2021).","journal-title":"Chem. Rev."},{"key":"2982_CR124","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1021\/acs.bioconjchem.1c00247","volume":"32","author":"J Kaur","year":"2021","unstructured":"Kaur, J., Saxena, M. & Rishi, N. An overview of recent advances in biomedical applications of click chemistry. Bioconjug. Chem. 32, 1455\u20131471 (2021).","journal-title":"Bioconjug. Chem."},{"key":"2982_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202107192","volume":"34","author":"HY Yoon","year":"2022","unstructured":"Yoon, H. Y. et al. Copper-free click chemistry: applications in drug delivery, cell tracking, and tissue engineering. Adv. Mater. 34, e2107192 (2022).","journal-title":"Adv. Mater."},{"key":"2982_CR126","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1021\/acs.chemrev.0c00799","volume":"121","author":"GS Kumar","year":"2021","unstructured":"Kumar, G. S. & Lin, Q. Light-triggered click chemistry. Chem. Rev. 121, 6991\u20137031 (2021).","journal-title":"Chem. Rev."},{"key":"2982_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202112375","volume":"61","author":"CJ Smedley","year":"2022","unstructured":"Smedley, C. J. et al. Accelerated SuFEx click chemistry for modular synthesis. Angew. Chem. Int. Ed. Engl. 61, e202112375 (2022).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2982_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206546","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Site-specific antibody assembly on nanoparticles via a versatile coating method for improved cell targeting. Adv. Sci. 10, e2206546 (2023).","journal-title":"Adv. Sci."},{"key":"2982_CR129","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2020).","journal-title":"Sci. Adv."},{"key":"2982_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122587","volume":"633","author":"B Yadav","year":"2023","unstructured":"Yadav, B. et al. RGD-decorated PLGA nanoparticles improved effectiveness and safety of cisplatin for lung cancer therapy. Int. J. Pharm. 633, 122587 (2023).","journal-title":"Int. J. Pharm."},{"key":"2982_CR131","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2021.10.028","volume":"340","author":"A Sheikh","year":"2021","unstructured":"Sheikh, A., Md, S. & Kesharwani, P. RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. J. Control Release 340, 221\u2013242 (2021).","journal-title":"J. Control Release"},{"key":"2982_CR132","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1021\/acsami.8b18843","volume":"11","author":"K Abstiens","year":"2019","unstructured":"Abstiens, K., Gregoritza, M. & Goepferich, A. M. Ligand DenSity And Linker Length Are Critical Factors For Multivalent Nanoparticle-receptor Interactions. ACS Appl. Mater. Interfaces 11, 1311\u20131320 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2982_CR133","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1021\/acsanm.9b01392","volume":"2","author":"F Biscaglia","year":"2019","unstructured":"Biscaglia, F. et al. Gold nanoparticle aggregates functionalized with cyclic RGD peptides for targeting and imaging of colorectal cancer cells. Acs Appl. Nano Mater. 2, 6436\u20136444 (2019).","journal-title":"Acs Appl. Nano Mater."},{"key":"2982_CR134","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcis.2022.07.045","volume":"627","author":"P Siani","year":"2022","unstructured":"Siani, P., Frigerio, G., Donadoni, E. & Di Valentin, C. Molecular dynamics simulations of cRGD-conjugated PEGylated TiO(2) nanoparticles for targeted photodynamic therapy. J. Colloid Interface Sci. 627, 126\u2013141 (2022).","journal-title":"J. Colloid Interface Sci."},{"key":"2982_CR135","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","volume":"181","author":"Z Zhao","year":"2020","unstructured":"Zhao, Z., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151\u2013167 (2020).","journal-title":"Cell"},{"key":"2982_CR136","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","volume":"117","author":"M Srinivasarao","year":"2017","unstructured":"Srinivasarao, M. & Low, P. S. Ligand-targeted drug delivery. Chem. Rev. 117, 12133\u201312164 (2017).","journal-title":"Chem. Rev."},{"key":"2982_CR137","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3892\/ijo.2026.5865","volume":"68","author":"N Merjaneh","year":"2026","unstructured":"Merjaneh, N. et al. FOXM1 inhibitor, RCM\u20111, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma. Int. J. Oncol. 68, 52 (2026).","journal-title":"Int. J. Oncol."},{"key":"2982_CR138","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1021\/acs.molpharmaceut.4c00663","volume":"21","author":"S Goksen","year":"2024","unstructured":"Goksen, S., Varan, G., Bilensoy, E. & Esendagli, G. Folate receptor beta (FRbeta) expression on myeloid cells and the impact of reticuloendothelial system on folate-functionalized nanoparticles\u2019 biodistribution in cancer. Mol. Pharm. 21, 4688\u20134699 (2024).","journal-title":"Mol. Pharm."},{"key":"2982_CR139","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.drudis.2020.03.009","volume":"25","author":"S Mignani","year":"2020","unstructured":"Mignani, S., Shi, X., Cena, V. & Majoral, J. P. Dendrimer- and polymeric nanoparticle-aptamer bioconjugates as nonviral delivery systems: a new approach in medicine. Drug Discov. Today 25, 1065\u20131073 (2020).","journal-title":"Drug Discov. Today"},{"key":"2982_CR140","doi-asserted-by":"publisher","first-page":"9123","DOI":"10.3390\/ijms21239123","volume":"21","author":"Z Fu","year":"2020","unstructured":"Fu, Z. & Xiang, J. Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. Int. J. Mol. Sci. 21, 9123 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR141","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1021\/jacs.2c02277","volume":"144","author":"J Ren","year":"2022","unstructured":"Ren, J. et al. Chemical and biophysical signatures of the protein corona in nanomedicine. J. Am. Chem. Soc. 144, 9184\u20139205 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"2982_CR142","doi-asserted-by":"publisher","first-page":"19667","DOI":"10.1021\/acsnano.3c02575","volume":"17","author":"CP Carney","year":"2023","unstructured":"Carney, C. P. et al. Impact of targeting moiety type and protein corona formation on the uptake of Fn14-targeted nanoparticles by cancer cells. ACS Nano. 17, 19667\u201319684 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR143","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941\u2013951 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2982_CR144","doi-asserted-by":"publisher","first-page":"20825","DOI":"10.1021\/acsnano.3c05853","volume":"17","author":"M Xu","year":"2023","unstructured":"Xu, M. et al. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance. ACS Nano 17, 20825\u201320849 (2023).","journal-title":"ACS Nano"},{"key":"2982_CR145","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1165\/rcmb.2020-0306TR","volume":"64","author":"Z Deng","year":"2021","unstructured":"Deng, Z., Kalin, G. T., Shi, D. & Kalinichenko, V. V. Nanoparticle delivery systems with cell-specific targeting for pulmonary diseases. Am. J. Respir. Cell Mol. Biol. 64, 292\u2013307 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR146","doi-asserted-by":"publisher","first-page":"e1800876","DOI":"10.1002\/adhm.201800876","volume":"7","author":"AW Dunn","year":"2018","unstructured":"Dunn, A. W., Kalinichenko, V. V. & Shi, D. Highly efficient in vivo targeting of the pulmonary endothelium using novel modifications of polyethylenimine: an importance of charge. Adv. Health. Mater. 7, e1800876 (2018).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300614","volume":"10","author":"Y Peng","year":"2023","unstructured":"Peng, Y. et al. Size-controlled DNA tile self-assembly nanostructures through caveolae-mediated endocytosis for signal-amplified imaging of MicroRNAs in living cells. Adv. Sci. 10, e2300614 (2023).","journal-title":"Adv. Sci."},{"key":"2982_CR148","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1021\/acsanm.1c00987","volume":"4","author":"J Dolai","year":"2021","unstructured":"Dolai, J., Mandal, K. & Jana, N. R. Nanoparticle size effects in biomedical applications. ACS Appl. Nano Mater. 4, 6471\u20136496 (2021).","journal-title":"ACS Appl. Nano Mater."},{"key":"2982_CR149","doi-asserted-by":"publisher","first-page":"1417834","DOI":"10.3389\/fphar.2024.1417834","volume":"15","author":"J Fan","year":"2024","unstructured":"Fan, J., Zheng, S., Wang, M. & Yuan, X. The critical roles of caveolin-1 in lung diseases. Front. Pharmacol. 15, 1417834 (2024).","journal-title":"Front. Pharmacol."},{"key":"2982_CR150","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.apsb.2020.11.020","volume":"11","author":"C Yang","year":"2021","unstructured":"Yang, C. et al. The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems. Acta Pharm. Sin. B. 11, 961\u2013977 (2021).","journal-title":"Acta Pharm. Sin. B."},{"key":"2982_CR151","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41586-020-2822-7","volume":"586","author":"A Gillich","year":"2020","unstructured":"Gillich, A. et al. Capillary cell-type specialization in the alveolus. Nature 586, 785\u2013789 (2020).","journal-title":"Nature"},{"key":"2982_CR152","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1164\/rccm.201906-1232OC","volume":"202","author":"C Bolte","year":"2020","unstructured":"Bolte, C. et al. Nanoparticle delivery of proangiogenic transcription factors into the neonatal circulation inhibits alveolar simplification caused by hyperoxia. Am. J. Respir. Crit. Care Med. 202, 100\u2013111 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR153","first-page":"43","volume":"17","author":"F Kohram","year":"2023","unstructured":"Kohram, F. et al. Demonstration of safety in wild type mice of npFOXF1, a novel nanoparticle-based gene therapy for alveolar capillary dysplasia with misaligned pulmonary veins. Biologics 17, 43\u201355 (2023).","journal-title":"Biologics"},{"key":"2982_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114195","volume":"184","author":"L Fu","year":"2022","unstructured":"Fu, L. et al. The role of the cell surface glycocalyx in drug delivery to and through the endothelium. Adv. Drug Deliv. Rev. 184, 114195 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR155","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1021\/acs.chemmater.8b00840","volume":"30","author":"JP Wang","year":"2018","unstructured":"Wang, J. P. et al. Targeting endothelial cell junctions with negatively charged gold nanoparticles. Chem. Mater. 30, 3759\u20133767 (2018).","journal-title":"Chem. Mater."},{"key":"2982_CR156","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.7150\/thno.16358","volume":"6","author":"B Chen","year":"2016","unstructured":"Chen, B. et al. Targeting negative surface charges of cancer cells by multifunctional nanoprobes. Theranostics 6, 1887\u20131898 (2016).","journal-title":"Theranostics"},{"key":"2982_CR157","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science 123, 309\u2013314 (1956).","journal-title":"Science"},{"key":"2982_CR158","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 41, 211\u2013218 (2016).","journal-title":"Trends Biochem Sci."},{"key":"2982_CR159","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1039\/C6NR07161A","volume":"9","author":"X Han","year":"2017","unstructured":"Han, X. et al. Biomarkerless targeting and photothermal cancer cell killing by surface-electrically-charged superparamagnetic Fe(3)O(4) composite nanoparticles. Nanoscale 9, 1457\u20131465 (2017).","journal-title":"Nanoscale"},{"key":"2982_CR160","doi-asserted-by":"publisher","first-page":"41986","DOI":"10.1021\/acsami.8b15098","volume":"10","author":"J Zhao","year":"2018","unstructured":"Zhao, J. et al. Electrical-charge-mediated cancer cell targeting via protein corona-decorated superparamagnetic nanoparticles in a simulated physiological environment. ACS Appl Mater. Interfaces 10, 41986\u201341998 (2018).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"2982_CR161","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2147\/IJN.S102138","volume":"11","author":"Y Ostrovski","year":"2016","unstructured":"Ostrovski, Y., Hofemeier, P. & Sznitman, J. Augmenting regional and targeted delivery in the pulmonary acinus using magnetic particles. Int. J. Nanomed. 11, 3385\u20133395 (2016).","journal-title":"Int. J. Nanomed."},{"key":"2982_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.110801","volume":"111","author":"K Reczynska","year":"2020","unstructured":"Reczynska, K. et al. Stimuli-sensitive fatty acid-based microparticles for the treatment of lung cancer. Mater. Sci. Eng. C. Mater. Biol. Appl. 111, 110801 (2020).","journal-title":"Mater. Sci. Eng. C. Mater. Biol. Appl."},{"key":"2982_CR163","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1021\/acs.molpharmaceut.7b00532","volume":"14","author":"DN Price","year":"2017","unstructured":"Price, D. N., Stromberg, L. R., Kunda, N. K. & Muttil, P. In vivo pulmonary delivery and magnetic-targeting of dry powder nano-in-microparticles. Mol. Pharm. 14, 4741\u20134750 (2017).","journal-title":"Mol. Pharm."},{"key":"2982_CR164","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/sctm.20-0004","volume":"9","author":"LHA Silva","year":"2020","unstructured":"Silva, L. H. A. et al. Magnetic targeting increases mesenchymal stromal cell retention in lungs and enhances beneficial effects on pulmonary damage in experimental silicosis. Stem Cells Transl. Med. 9, 1244\u20131256 (2020).","journal-title":"Stem Cells Transl. Med."},{"key":"2982_CR165","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/biomedicines9070803","volume":"9","author":"R Sanwal","year":"2021","unstructured":"Sanwal, R. et al. Ultrasound and microbubbles for targeted drug delivery to the lung endothelium in ARDS: cellular mechanisms and therapeutic opportunities. Biomedicines 9, 803 (2021).","journal-title":"Biomedicines"},{"key":"2982_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02883-w","volume":"22","author":"M Li","year":"2024","unstructured":"Li, M. et al. Ultrasound-responsive nanocarriers with siRNA and Fe(3)O(4) regulate macrophage polarization and phagocytosis for augmented non-small cell lung cancer immunotherapy. J. Nanobiotechnol. 22, 605 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2982_CR167","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","volume":"85","author":"J Weers","year":"2015","unstructured":"Weers, J. Inhaled antimicrobial therapy\u2014barriers to effective treatment. Adv. Drug Deliv. Rev. 85, 24\u201343 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR168","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/pharmaceutics8010006","volume":"8","author":"D Cipolla","year":"2016","unstructured":"Cipolla, D., Blanchard, J. & Gonda, I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics 8, 6 (2016).","journal-title":"Pharmaceutics"},{"key":"2982_CR169","doi-asserted-by":"publisher","first-page":"100966","DOI":"10.1016\/j.mtbio.2024.100966","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Pulmonary inhalation for disease treatment: basic research and clinical translations. Mater. Today Bio. 25, 100966 (2024).","journal-title":"Mater. Today Bio."},{"key":"2982_CR170","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejpb.2019.09.020","volume":"144","author":"C Garcia-Mouton","year":"2019","unstructured":"Garcia-Mouton, C., Hidalgo, A., Cruz, A. & Perez-Gil, J. The lord of the lungs: the essential role of pulmonary surfactant upon inhalation of nanoparticles. Eur. J. Pharm. Biopharm. 144, 230\u2013243 (2019).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2982_CR171","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/jamp.2020.29029.cd","volume":"33","author":"C Darquenne","year":"2020","unstructured":"Darquenne, C. Deposition mechanisms. J. Aerosol. Med. Pulm. Drug Deliv. 33, 181\u2013185 (2020).","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"2982_CR172","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.jaci.2016.11.036","volume":"139","author":"S Jabbal","year":"2017","unstructured":"Jabbal, S., Poli, G. & Lipworth, B. Does size really matter?: Relationship of particle size to lung deposition and exhaled fraction. J. Allergy Clin. Immunol. 139, 2013\u20132014 e2011 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2982_CR173","first-page":"539","volume":"20","author":"Y Yu","year":"2023","unstructured":"Yu, Y. et al. Increasing stiffness promotes pulmonary retention of ligand-directed dexamethasone-loaded nanoparticle for enhanced acute lung inflammation therapy. Bioact. Mater. 20, 539\u2013547 (2023).","journal-title":"Bioact. Mater."},{"key":"2982_CR174","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/acs.molpharmaceut.4c00128","volume":"21","author":"S Alwani","year":"2024","unstructured":"Alwani, S., Wasan, E. K. & Badea, I. Solid lipid nanoparticles for pulmonary delivery of biopharmaceuticals: a review of opportunities, challenges, and delivery applications. Mol. Pharm. 21, 3084\u20133102 (2024).","journal-title":"Mol. Pharm."},{"key":"2982_CR175","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/ijms25031933","volume":"25","author":"M Abrami","year":"2024","unstructured":"Abrami, M. et al. Mucus structure, viscoelastic properties, and composition in chronic respiratory diseases. Int. J. Mol. Sci. 25, 1933 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR176","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.addr.2017.10.009","volume":"124","author":"X Murgia","year":"2018","unstructured":"Murgia, X. et al. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv. Drug Deliv. Rev. 124, 82\u201397 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR177","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/17425247.2021.1854222","volume":"18","author":"D Chen","year":"2021","unstructured":"Chen, D., Liu, J., Wu, J. & Suk, J. S. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin. Drug Deliv. 18, 595\u2013606 (2021).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2982_CR178","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4155\/tde-2015-0002","volume":"7","author":"JP Pearson","year":"2016","unstructured":"Pearson, J. P., Chater, P. I. & Wilcox, M. D. The properties of the mucus barrier, a unique gel\u2013how can nanoparticles cross it? Ther. Deliv. 7, 229\u2013244 (2016).","journal-title":"Ther. Deliv."},{"key":"2982_CR179","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1021\/acs.biomac.6b00164","volume":"17","author":"X Murgia","year":"2016","unstructured":"Murgia, X. et al. Size-limited penetration of nanoparticles into porcine respiratory mucus after aerosol deposition. Biomacromolecules 17, 1536\u20131542 (2016).","journal-title":"Biomacromolecules"},{"key":"2982_CR180","doi-asserted-by":"publisher","first-page":"2300619","DOI":"10.1183\/13993003.00619-2023","volume":"61","author":"BF Dickey","year":"2023","unstructured":"Dickey, B. F. & Evans, C. M. Towards a better mucolytic. Eur. Respir. J. 61, 2300619 (2023).","journal-title":"Eur. Respir. J."},{"key":"2982_CR181","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1021\/acsnano.2c11147","volume":"17","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Mucus penetration of surface-engineered nanoparticles in various pH microenvironments. ACS Nano. 17, 2813\u20132828 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR182","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","volume":"124","author":"JT Huckaby","year":"2018","unstructured":"Huckaby, J. T. & Lai, S. K. PEGylation for enhancing nanoparticle diffusion in mucus. Adv. Drug Deliv. Rev. 124, 125\u2013139 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR183","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","volume":"9","author":"Q Xu","year":"2015","unstructured":"Xu, Q. et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano. 9, 9217\u20139227 (2015).","journal-title":"ACS Nano."},{"key":"2982_CR184","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/acs.biomac.5b01480","volume":"17","author":"EF Craparo","year":"2016","unstructured":"Craparo, E. F. et al. Pegylated polyaspartamide-polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus. Biomacromolecules 17, 767\u2013777 (2016).","journal-title":"Biomacromolecules"},{"key":"2982_CR185","doi-asserted-by":"publisher","first-page":"23814","DOI":"10.1021\/acsnano.3c07932","volume":"17","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Poly(ethyl ethylene phosphate): overcoming the \u201cpolyethylene glycol dilemma\u201d for cancer immunotherapy and mRNA vaccination. ACS Nano. 17, 23814\u201323828 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR186","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-bioeng-062117-121156","volume":"20","author":"TL Carlson","year":"2018","unstructured":"Carlson, T. L., Lock, J. Y. & Carrier, R. L. Engineering the mucus barrier. Annu Rev. Biomed. Eng. 20, 197\u2013220 (2018).","journal-title":"Annu Rev. Biomed. Eng."},{"key":"2982_CR187","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mattod.2023.11.011","volume":"72","author":"K Park","year":"2024","unstructured":"Park, K. et al. Nitric oxide-assisted mucus-walking zwitterionic nanocomplexes for synergistic treatment of severe respiratory infectious disease. Mater. Today 72, 57\u201370 (2024).","journal-title":"Mater. Today"},{"key":"2982_CR188","doi-asserted-by":"publisher","first-page":"32567","DOI":"10.1021\/jacs.4c11347","volume":"146","author":"AY Jiang","year":"2024","unstructured":"Jiang, A. Y. et al. Zwitterionic polymer-functionalized lipid nanoparticles for the nebulized delivery of mRNA. J. Am. Chem. Soc. 146, 32567\u201332574 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"2982_CR189","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.actbio.2022.05.038","volume":"147","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. The influence of a biomimetic pulmonary surfactant modification on the in vivo fate of nanoparticles in the lung. Acta Biomater. 147, 391\u2013402 (2022).","journal-title":"Acta Biomater."},{"key":"2982_CR190","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1021\/acs.molpharmaceut.1c00770","volume":"19","author":"A Kumari","year":"2022","unstructured":"Kumari, A. et al. Surface-engineered mucus penetrating nucleic acid delivery systems with cell penetrating peptides for the lungs. Mol. Pharm. 19, 1309\u20131324 (2022).","journal-title":"Mol. Pharm."},{"key":"2982_CR191","doi-asserted-by":"crossref","unstructured":"Yang, M. Y. et al. Dual barrier-penetrating inhaled nanoparticles for enhanced idiopathic pulmonary fibrosis therapy. Adv. Funct. Mater. 34, 2315128 (2024).","DOI":"10.1002\/adfm.202315128"},{"key":"2982_CR192","doi-asserted-by":"publisher","first-page":"eadt2752","DOI":"10.1126\/sciadv.adt2752","volume":"11","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. Hydrogen-induced disruption of the airway mucus barrier enhances nebulized RNA delivery to reverse pulmonary fibrosis. Sci. Adv. 11, eadt2752 (2025).","journal-title":"Sci. Adv."},{"key":"2982_CR193","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drudis.2019.09.023","volume":"25","author":"Q Liu","year":"2020","unstructured":"Liu, Q. et al. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discov. Today 25, 150\u2013159 (2020).","journal-title":"Drug Discov. Today"},{"key":"2982_CR194","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.nano.2016.02.020","volume":"12","author":"E Seydoux","year":"2016","unstructured":"Seydoux, E. et al. Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4(+) T cell proliferation. Nanomedicine 12, 1815\u20131826 (2016).","journal-title":"Nanomedicine"},{"key":"2982_CR195","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.nano.2015.11.002","volume":"12","author":"CA Fromen","year":"2016","unstructured":"Fromen, C. A. et al. Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. Nanomedicine 12, 677\u2013687 (2016).","journal-title":"Nanomedicine"},{"key":"2982_CR196","first-page":"262","volume":"33","author":"WT Lee","year":"2024","unstructured":"Lee, W. T. et al. Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. Bioact. Mater. 33, 262\u2013278 (2024).","journal-title":"Bioact. Mater."},{"key":"2982_CR197","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cocis.2017.08.001","volume":"31","author":"MJ Guichard","year":"2017","unstructured":"Guichard, M. J., Leal, T. & Vanbever, R. PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals. Curr. Opin. Colloid Interface Sci. 31, 43\u201350 (2017).","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"2982_CR198","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejpb.2013.09.006","volume":"86","author":"M Murata","year":"2014","unstructured":"Murata, M., Tahara, K. & Takeuchi, H. Real-time in vivo imaging of surface-modified liposomes to evaluate their behavior after pulmonary administration. Eur. J. Pharm. Biopharm. 86, 115\u2013119 (2014).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2982_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202300226","volume":"12","author":"S Jung","year":"2023","unstructured":"Jung, S. et al. Zwitterionic inhaler with synergistic therapeutics for reprogramming of M2 macrophage to pro-inflammatory phenotype. Adv. Health. Mater. 12, e2300226 (2023).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.758941","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Surfactant proteins A\/D-CD14 on alveolar macrophages is a common pathway associated with phagocytosis of nanomaterials and cytokine production. Front. Immunol. 12, 758941 (2021).","journal-title":"Front. Immunol."},{"key":"2982_CR201","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front. Microbiol. 9, 915 (2018).","journal-title":"Front. Microbiol."},{"key":"2982_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112551","volume":"134","author":"S Carregal-Romero","year":"2022","unstructured":"Carregal-Romero, S. et al. Delayed alveolar clearance of nanoparticles through control of coating composition and interaction with lung surfactant protein A. Biomater. Adv. 134, 112551 (2022).","journal-title":"Biomater. Adv."},{"key":"2982_CR203","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.1021\/acsnano.3c02075","volume":"17","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. An inhalable hybrid biomimetic nanoplatform for sequential drug release and remodeling lung immune homeostasis in acute lung injury treatment. ACS Nano. 17, 11626\u201311644 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR204","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"2982_CR205","doi-asserted-by":"publisher","first-page":"14219","DOI":"10.2147\/IJN.S545306","volume":"20","author":"J Gou","year":"2025","unstructured":"Gou, J. et al. Inhalable exosomes in respiratory therapies with the transformative potential. Int. J. Nanomed. 20, 14219\u201314252 (2025).","journal-title":"Int. J. Nanomed."},{"key":"2982_CR206","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/pharmaceutics18020168","volume":"18","author":"JW Lee","year":"2026","unstructured":"Lee, J. W. et al. Inhalation-based nanoparticle drug delivery targeting the diseased lower airways in idiopathic pulmonary fibrosis. Pharmaceutics 18, 168 (2026).","journal-title":"Pharmaceutics"},{"key":"2982_CR207","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/pharmaceutics17070893","volume":"17","author":"DE Mahmoud","year":"2025","unstructured":"Mahmoud, D. E. et al. Inhalable nanotechnology-based drug delivery systems for the treatment of inflammatory lung diseases. Pharmaceutics 17, 893 (2025).","journal-title":"Pharmaceutics"},{"key":"2982_CR208","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s11095-022-03286-y","volume":"39","author":"R Kumar","year":"2022","unstructured":"Kumar, R. et al. Nanotechnology-assisted metered-dose inhalers (MDIs) for high-performance pulmonary drug delivery applications. Pharm. Res. 39, 2831\u20132855 (2022).","journal-title":"Pharm. Res."},{"key":"2982_CR209","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1089\/jamp.2024.29117.mk","volume":"37","author":"HM Mansour","year":"2024","unstructured":"Mansour, H. M., Muralidharan, P. & Hayes, D. Jr. Inhaled nanoparticulate systems: composition, manufacture and aerosol delivery. J. Aerosol. Med. Pulm. Drug Deliv. 37, 202\u2013218 (2024).","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"2982_CR210","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1080\/10717544.2017.1402217","volume":"24","author":"N Li","year":"2017","unstructured":"Li, N. et al. Surfactant protein-A nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury. Drug Deliv. 24, 1770\u20131781 (2017).","journal-title":"Drug Deliv."},{"key":"2982_CR211","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.2147\/IJN.S415063","volume":"18","author":"J Nowak-Jary","year":"2023","unstructured":"Nowak-Jary, J. & Machnicka, B. In vivo biodistribution and clearance of magnetic iron oxide nanoparticles for medical applications. Int. J. Nanomed. 18, 4067\u20134100 (2023).","journal-title":"Int. J. Nanomed."},{"key":"2982_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48838-5","volume":"15","author":"IV Zelepukin","year":"2024","unstructured":"Zelepukin, I. V., Shevchenko, K. G. & Deyev, S. M. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery. Nat. Commun. 15, 4366 (2024).","journal-title":"Nat. Commun."},{"key":"2982_CR213","doi-asserted-by":"publisher","first-page":"48284","DOI":"10.1021\/acsami.0c12341","volume":"12","author":"SM Pustulka","year":"2020","unstructured":"Pustulka, S. M., Ling, K., Pish, S. L. & Champion, J. A. Protein nanoparticle charge and hydrophobicity govern protein corona and macrophage uptake. ACS Appl. Mater. Interfaces 12, 48284\u201348295 (2020).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2982_CR214","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.1021\/acsnano.0c02289","volume":"14","author":"Y Zou","year":"2020","unstructured":"Zou, Y. et al. Polyglycerol grafting shields nanoparticles from protein corona formation to avoid macrophage uptake. ACS Nano 14, 7216\u20137226 (2020).","journal-title":"ACS Nano"},{"key":"2982_CR215","doi-asserted-by":"crossref","unstructured":"Chen, Y., Su, Y.-C. & Roffler, S. R. Polyethylene glycol immunogenicity in nanomedicine. Nat. Rev. Bioeng. 3, 742\u2013760 (2025).","DOI":"10.1038\/s44222-025-00321-6"},{"key":"2982_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119680","volume":"231","author":"S Peng","year":"2020","unstructured":"Peng, S. et al. Biodegradable zwitterionic polymer membrane coating endowing nanoparticles with ultra-long circulation and enhanced tumor photothermal therapy. Biomaterials 231, 119680 (2020).","journal-title":"Biomaterials"},{"key":"2982_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57648-2","volume":"16","author":"R Tavano","year":"2025","unstructured":"Tavano, R. et al. Species differences in opsonization and phagocyte recognition of preclinical poly-2-alkyl-2-oxazoline-coated nanoparticles. Nat. Commun. 16, 2642 (2025).","journal-title":"Nat. Commun."},{"key":"2982_CR218","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/nano10040787","volume":"10","author":"SY Fam","year":"2020","unstructured":"Fam, S. Y. et al. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials 10, 787 (2020).","journal-title":"Nanomaterials"},{"key":"2982_CR219","doi-asserted-by":"publisher","first-page":"e1706759","DOI":"10.1002\/adma.201706759","volume":"30","author":"RH Fang","year":"2018","unstructured":"Fang, R. H., Kroll, A. V., Gao, W. & Zhang, L. Cell membrane coating nanotechnology. Adv. Mater. 30, e1706759 (2018).","journal-title":"Adv. Mater."},{"key":"2982_CR220","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.1021\/nn401317t","volume":"7","author":"K Kusumoto","year":"2013","unstructured":"Kusumoto, K. et al. Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS Nano. 7, 7534\u20137541 (2013).","journal-title":"ACS Nano."},{"key":"2982_CR221","doi-asserted-by":"publisher","first-page":"1807677","DOI":"10.1002\/adfm.201807677","volume":"29","author":"MM Abd Elwakil","year":"2019","unstructured":"Abd Elwakil, M. M. et al. Lung-endothelium-targeted nanoparticles based on a ph-sensitive lipid and the GALA Peptide enable robust gene silencing and the regression of metastatic lung cancer. Adv. Funct. Mater. 29, 1807677 (2019).","journal-title":"Adv. Funct. Mater."},{"key":"2982_CR222","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR223","first-page":"1","volume":"31","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. Fluorinated amphiphilic Poly(beta-Amino ester) nanoparticle for highly efficient and specific delivery of nucleic acids to the lung capillary endothelium. Bioact. Mater. 31, 1\u201317 (2024).","journal-title":"Bioact. Mater."},{"key":"2982_CR224","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1021\/acsnano.8b07231","volume":"13","author":"D Yang","year":"2019","unstructured":"Yang, D. et al. Transferrin functionization elevates transcytosis of nanogranules across epithelium by triggering polarity-associated transport flow and positive cellular feedback loop. ACS Nano. 13, 5058\u20135076 (2019).","journal-title":"ACS Nano."},{"key":"2982_CR225","doi-asserted-by":"publisher","first-page":"eadv9571","DOI":"10.1126\/sciadv.adv9571","volume":"11","author":"Z Chen","year":"2025","unstructured":"Chen, Z. et al. Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis. Sci. Adv. 11, eadv9571 (2025).","journal-title":"Sci. Adv."},{"key":"2982_CR226","doi-asserted-by":"publisher","first-page":"e172058","DOI":"10.1172\/JCI172058","volume":"133","author":"J May","year":"2023","unstructured":"May, J., Mitchell, J. A. & Jenkins, R. G. Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis. J. Clin. Invest. 133, e172058 (2023).","journal-title":"J. Clin. Invest."},{"key":"2982_CR227","doi-asserted-by":"publisher","first-page":"eabf7820","DOI":"10.1126\/sciadv.abf7820","volume":"7","author":"JH Park","year":"2021","unstructured":"Park, J. H. et al. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Sci. Adv. 7, eabf7820 (2021).","journal-title":"Sci. Adv."},{"key":"2982_CR228","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/biomedicines9101496","volume":"9","author":"MH Akhter","year":"2021","unstructured":"Akhter, M. H. et al. Impact of protein corona on the biological identity of nanomedicine: understanding the fate of nanomaterials in the biological milieu. Biomedicines 9, 1496 (2021).","journal-title":"Biomedicines"},{"key":"2982_CR229","doi-asserted-by":"publisher","first-page":"00591","DOI":"10.1183\/23120541.00591-2021","volume":"8","author":"Q Zheng","year":"2022","unstructured":"Zheng, Q. et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 8, 00591\u20132021 (2022).","journal-title":"ERJ Open Res."},{"key":"2982_CR230","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/crj.13466","volume":"16","author":"DS Glass","year":"2022","unstructured":"Glass, D. S. et al. Idiopathic pulmonary fibrosis: current and future treatment. Clin. Respir. J. 16, 84\u201396 (2022).","journal-title":"Clin. Respir. J."},{"key":"2982_CR231","doi-asserted-by":"publisher","first-page":"797292","DOI":"10.3389\/fphar.2021.797292","volume":"12","author":"Q Mei","year":"2021","unstructured":"Mei, Q. et al. Idiopathic pulmonary fibrosis: an update on pathogenesis. Front. Pharmacol. 12, 797292 (2021).","journal-title":"Front. Pharmacol."},{"key":"2982_CR232","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1755-1536-5-11","volume":"5","author":"NW Todd","year":"2012","unstructured":"Todd, N. W., Luzina, I. G. & Atamas, S. P. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenes. Tissue Repair. 5, 11 (2012).","journal-title":"Fibrogenes. Tissue Repair."},{"key":"2982_CR233","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555\u2013566 (2020).","journal-title":"Nature"},{"key":"2982_CR234","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2014.00123","volume":"5","author":"RT Kendall","year":"2014","unstructured":"Kendall, R. T. & Feghali-Bostwick, C. A. Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol. 5, 123 (2014).","journal-title":"Front. Pharmacol."},{"key":"2982_CR235","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12931-024-02898-9","volume":"25","author":"X Ju","year":"2024","unstructured":"Ju, X. et al. Regulation of myofibroblast dedifferentiation in pulmonary fibrosis. Respir. Res. 25, 284 (2024).","journal-title":"Respir. Res."},{"key":"2982_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10839-0","volume":"10","author":"V Kheirollahi","year":"2019","unstructured":"Kheirollahi, V. et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat. Commun. 10, 2987 (2019).","journal-title":"Nat. Commun."},{"key":"2982_CR237","doi-asserted-by":"crossref","unstructured":"Huang, E. et al. The roles of immune cells in the pathogenesis of fibrosis. Int. J. Mol. Sci. 21, 5203 (2020).","DOI":"10.3390\/ijms21155203"},{"key":"2982_CR238","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","volume":"18","author":"RL Gieseck 3rd","year":"2018","unstructured":"Gieseck, R. L. 3rd, Wilson, M. S. & Wynn, T. A. Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol. 18, 62\u201376 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2982_CR239","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao, M. et al. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct. Target Ther. 7, 206 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR240","doi-asserted-by":"publisher","first-page":"C1046","DOI":"10.1152\/ajpcell.00302.2023","volume":"325","author":"CY Perrot","year":"2023","unstructured":"Perrot, C. Y., Karampitsakos, T. & Herazo-Maya, J. D. Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis. Am. J. Physiol. Cell Physiol. 325, C1046\u2013C1057 (2023).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2982_CR241","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3390\/biomedicines10061423","volume":"10","author":"E Ortiz-Zapater","year":"2022","unstructured":"Ortiz-Zapater, E., Signes-Costa, J., Montero, P. & Roger, I. Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts? Biomedicines 10, 1423 (2022).","journal-title":"Biomedicines"},{"key":"2982_CR242","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.3390\/ijms24108749","volume":"24","author":"W Zhao","year":"2023","unstructured":"Zhao, W. et al. Injured endothelial cell: a risk factor for pulmonary fibrosis. Int. J. Mol. Sci. 24, 8749 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR243","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1165\/rcmb.2020-0504OC","volume":"66","author":"T Yanagihara","year":"2022","unstructured":"Yanagihara, T. et al. Connective-tissue growth factor contributes to TGF-beta1-induced lung fibrosis. Am. J. Respir. Cell Mol. Biol. 66, 260\u2013270 (2022).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR244","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.devcel.2011.07.001","volume":"21","author":"A Armulik","year":"2011","unstructured":"Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell. 21, 193\u2013215 (2011).","journal-title":"Dev. Cell."},{"key":"2982_CR245","doi-asserted-by":"crossref","unstructured":"Leonard-Duke, J., Hung, C., Sharma, A. & Peirce, S. M. Multi-scale computational model of endothelial cell-pericyte coupling in idiopathic pulmonary fibrosis. Faseb Journal. 36, (2022).","DOI":"10.1096\/fasebj.2022.36.S1.R6252"},{"key":"2982_CR246","doi-asserted-by":"crossref","unstructured":"Hung, C. & Altemeier, W. Angiogenic role of lung pericytes in experimental viral lung injury. FASEB J. 36, (2022).","DOI":"10.1096\/fasebj.2022.36.S1.R4124"},{"key":"2982_CR247","doi-asserted-by":"publisher","first-page":"1150028","DOI":"10.3389\/fphys.2023.1150028","volume":"14","author":"AT Garrison","year":"2023","unstructured":"Garrison, A. T., Bignold, R. E., Wu, X. & Johnson, J. R. Pericytes: the lung-forgotten cell type. Front. Physiol. 14, 1150028 (2023).","journal-title":"Front. Physiol."},{"key":"2982_CR248","doi-asserted-by":"crossref","unstructured":"GGao, W. et al. Emergence of fibrotic pericytes and their transcriptional regulation in pulmonary fibrosis. Nat. Commun. 17, 5142 (2026).","DOI":"10.1038\/s41467-026-74910-3"},{"key":"2982_CR249","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI60323","volume":"122","author":"PW Noble","year":"2012","unstructured":"Noble, P. W., Barkauskas, C. E. & Jiang, D. Pulmonary fibrosis: patterns and perpetrators. J. Clin. Invest. 122, 2756\u20132762 (2012).","journal-title":"J. Clin. Invest."},{"key":"2982_CR250","doi-asserted-by":"publisher","first-page":"109482","DOI":"10.1016\/j.cellsig.2019.109482","volume":"66","author":"M Selman","year":"2020","unstructured":"Selman, M. & Pardo, A. The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. Cell Signal. 66, 109482 (2020).","journal-title":"Cell Signal."},{"key":"2982_CR251","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/medicina55040083","volume":"55","author":"F Salton","year":"2019","unstructured":"Salton, F., Volpe, M. C. & Confalonieri, M. Epithelial(-)mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis. Medicina 55, 83 (2019).","journal-title":"Medicina"},{"key":"2982_CR252","doi-asserted-by":"crossref","unstructured":"Yang, M.-Y. et al. Dual barrier-penetrating inhaled nanoparticles for enhanced idiopathic pulmonary fibrosis therapy. Adv. Funct. Mater. 34, 2315128 (2024).","DOI":"10.1002\/adfm.202315128"},{"key":"2982_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106370","volume":"183","author":"M Massaro","year":"2023","unstructured":"Massaro, M. et al. Lipid nanoparticle-mediated mRNA delivery in lung fibrosis. Eur. J. Pharm. Sci. 183, 106370 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2982_CR254","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7162","volume":"8","author":"X Bai","year":"2022","unstructured":"Bai, X. et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci. Adv. 8, eabn7162 (2022).","journal-title":"Sci. Adv."},{"key":"2982_CR255","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2020.03.016","volume":"322","author":"J Kim","year":"2020","unstructured":"Kim, J. et al. Lung-targeted delivery of TGF-beta antisense oligonucleotides to treat pulmonary fibrosis. J. Control Release 322, 108\u2013121 (2020).","journal-title":"J. Control Release"},{"key":"2982_CR256","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.7150\/thno.54217","volume":"11","author":"J Hou","year":"2021","unstructured":"Hou, J. et al. Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy. Theranostics 11, 3244\u20133261 (2021).","journal-title":"Theranostics"},{"key":"2982_CR257","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121098119","volume":"119","author":"A Singh","year":"2022","unstructured":"Singh, A. et al. Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. Proc. Natl. Acad. Sci. Usa. 119, e2121098119 (2022).","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"2982_CR258","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4791","volume":"10","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice. Sci. Adv. 10, eado4791 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR259","doi-asserted-by":"crossref","unstructured":"Jin, H. et al. Engineered lipid nanoparticles for the treatment of pulmonary fibrosis by regulating epithelial-mesenchymal transition in the lungs. Adv. Funct. Mater. 33, 2209432 (2023).","DOI":"10.1002\/adfm.202209432"},{"key":"2982_CR260","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1021\/acsnano.2c11112","volume":"17","author":"X Li","year":"2023","unstructured":"Li, X. et al. ROS-responsive Janus Au\/mesoporous silica core\/shell nanoparticles for drug delivery and long-term CT imaging tracking of MSCs in pulmonary fibrosis treatment. ACS Nano. 17, 6387\u20136399 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR261","doi-asserted-by":"publisher","first-page":"L190","DOI":"10.1152\/ajplung.00086.2022","volume":"324","author":"RS Knipe","year":"2023","unstructured":"Knipe, R. S. et al. Myofibroblast-specific inhibition of the Rho kinase-MRTF-SRF pathway using nanotechnology for the prevention of pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 324, L190\u2013L198 (2023).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2982_CR262","doi-asserted-by":"publisher","first-page":"15354","DOI":"10.1021\/acsnano.2c10388","volume":"17","author":"J Li","year":"2023","unstructured":"Li, J. et al. Pulmonary delivery of specialized pro-resolving mediators-based nanotherapeutics attenuates pulmonary fibrosis in preclinical animal models. ACS Nano. 17, 15354\u201315370 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR263","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.actbio.2023.12.006","volume":"174","author":"J Hou","year":"2024","unstructured":"Hou, J. et al. Spatial targeting of fibrosis-promoting macrophages with nanoscale metal-organic frameworks for idiopathic pulmonary fibrosis therapy. Acta Biomater. 174, 372\u2013385 (2024).","journal-title":"Acta Biomater."},{"key":"2982_CR264","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba3167","volume":"6","author":"X Chang","year":"2020","unstructured":"Chang, X. et al. Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis. Sci. Adv. 6, eaba3167 (2020).","journal-title":"Sci. Adv."},{"key":"2982_CR265","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcis.2023.01.007","volume":"636","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatment. J. Colloid Interface Sci. 636, 388\u2013400 (2023).","journal-title":"J. Colloid Interface Sci."},{"key":"2982_CR266","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1039\/D0NR00750A","volume":"12","author":"X Chang","year":"2020","unstructured":"Chang, X. et al. Nanoengineered immunosuppressive therapeutics modulating M1\/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy. Nanoscale 12, 8664\u20138678 (2020).","journal-title":"Nanoscale"},{"key":"2982_CR267","doi-asserted-by":"crossref","unstructured":"Cao, X. et al. Co-delivery of astaxanthin and siTGF-\u03b21 via ionizable liposome nanoparticles for improved idiopathic pulmonary fibrosis therapy. ACS Appl. Mater. Interfaces 16, 20260\u201320272 (2024).","DOI":"10.1021\/acsami.4c01953"},{"key":"2982_CR268","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1473-3099(24)00176-2","volume":"24","author":"GBDLR Infections","year":"2024","unstructured":"Infections, G. B. D. L. R. & Antimicrobial Resistance, C. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect. Dis. 24, 974\u20131002 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2982_CR269","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-024-02093-8","volume":"10","author":"K Xiao","year":"2025","unstructured":"Xiao, K. et al. A pan-immune panorama of bacterial pneumonia revealed by a large-scale single-cell transcriptome atlas. Signal Transduct. Target Ther. 10, 5 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR270","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fmicb.2020.00928","volume":"11","author":"MH Muhammad","year":"2020","unstructured":"Muhammad, M. H. et al. Beyond risk: bacterial biofilms and their regulating approaches. Front. Microbiol. 11, 928 (2020).","journal-title":"Front. Microbiol."},{"key":"2982_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-024-00497-6","volume":"10","author":"S Gao","year":"2024","unstructured":"Gao, S. et al. Bacterial capsules: occurrence, mechanism, and function. NPJ Biofilms Microbiomes 10, 21 (2024).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2982_CR272","doi-asserted-by":"publisher","first-page":"e00107","DOI":"10.1128\/CMR.00107-18","volume":"32","author":"JA Grousd","year":"2019","unstructured":"Grousd, J. A., Rich, H. E. & Alcorn, J. F. Host-pathogen interactions in gram-positive bacterial pneumonia. Clin. Microbiol. Rev. 32, e00107\u201318 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"2982_CR273","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/jof7020079","volume":"7","author":"J Talapko","year":"2021","unstructured":"Talapko, J. et al. Candida albicans-the virulence factors and clinical manifestations of infection. J. Fungi 7, 79 (2021).","journal-title":"J. Fungi"},{"key":"2982_CR274","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.adf8972","volume":"381","author":"DJ Santana","year":"2023","unstructured":"Santana, D. J. et al. A Candida auris-specific adhesin, Scf1, governs surface association, colonization, and virulence. Science 381, 1461\u20131467 (2023).","journal-title":"Science"},{"key":"2982_CR275","doi-asserted-by":"crossref","unstructured":"Balducci, E., Papi, F., Capialbi, D. E. & Del Bino, L. Polysaccharides\u2019 structures and functions in biofilm architecture of antimicrobial-resistant (AMR) pathogens. Int. J. Mol. Sci. 24, 4030 (2023).","DOI":"10.3390\/ijms24044030"},{"key":"2982_CR276","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1126\/science.aat9689","volume":"364","author":"DJ Greenwood","year":"2019","unstructured":"Greenwood, D. J. et al. Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages. Science 364, 1279\u20131282 (2019).","journal-title":"Science"},{"key":"2982_CR277","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.chom.2023.02.002","volume":"31","author":"LJ Jia","year":"2023","unstructured":"Jia, L. J. et al. Aspergillus fumigatus hijacks human p11 to redirect fungal-containing phagosomes to non-degradative pathway. Cell Host Microbe 31, 373\u2013388 e310 (2023).","journal-title":"Cell Host Microbe"},{"key":"2982_CR278","doi-asserted-by":"publisher","first-page":"e00103","DOI":"10.1128\/CMR.00103-20","volume":"34","author":"N Clementi","year":"2021","unstructured":"Clementi, N. et al. Viral respiratory pathogens and lung injury. Clin. Microbiol. Rev. 34, e00103\u201320 (2021).","journal-title":"Clin. Microbiol. Rev."},{"key":"2982_CR279","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/pharmaceutics17020207","volume":"17","author":"H Omidian","year":"2025","unstructured":"Omidian, H. & Wilson, R. L. PLGA-based strategies for intranasal and pulmonary applications. Pharmaceutics 17, 207 (2025).","journal-title":"Pharmaceutics"},{"key":"2982_CR280","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.3390\/ijms24054333","volume":"24","author":"X Guo","year":"2023","unstructured":"Guo, X. et al. PLGA-based micro\/nanoparticles: an overview of their applications in respiratory diseases. Int. J. Mol. Sci. 24, 4333 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR281","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2017.09.015","volume":"127","author":"W Gao","year":"2018","unstructured":"Gao, W. et al. Nanoparticle-based local antimicrobial drug delivery. Adv. Drug Deliv. Rev. 127, 46\u201357 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR282","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.ebiom.2021.103699","volume":"74","author":"MN Vu","year":"2021","unstructured":"Vu, M. N., Kelly, H. G., Kent, S. J. & Wheatley, A. K. Current and future nanoparticle vaccines for COVID-19. EBioMedicine 74, 103699 (2021).","journal-title":"EBioMedicine"},{"key":"2982_CR283","doi-asserted-by":"crossref","unstructured":"Ren, H.-M. et al. Inhalable responsive polysaccharide-based antibiotic delivery nanoparticles to overcome mucus barrier for lung infection treatment. Nano Today 44, 101489 (2022)","DOI":"10.1016\/j.nantod.2022.101489"},{"key":"2982_CR284","doi-asserted-by":"crossref","unstructured":"Pan, X. T. et al. Inhalable MOF-derived nanoparticles for sonodynamic therapy of bacterial pneumonia. Adv. Funct. Mater. 32, 2205123 (2022).","DOI":"10.1002\/adfm.202112145"},{"key":"2982_CR285","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1083007","volume":"14","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection. Front. Microbiol. 14, 1083007 (2023).","journal-title":"Front. Microbiol."},{"key":"2982_CR286","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41565-024-01618-0","volume":"19","author":"B Li","year":"2024","unstructured":"Li, B. et al. Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles. Nat. Nanotechnol. 19, 834\u2013845 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR287","doi-asserted-by":"publisher","DOI":"10.34133\/research.0096","volume":"6","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Inflammation and microbiota regulation potentiate pneumonia therapy by biomimetic bacteria and macrophage membrane nanosystem. Research 6, 0096 (2023).","journal-title":"Research"},{"key":"2982_CR288","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk9754","volume":"10","author":"X Peng","year":"2024","unstructured":"Peng, X. et al. Biofunctional lipid nanoparticles for precision treatment and prophylaxis of bacterial infections. Sci. Adv. 10, eadk9754 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR289","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41563-022-01360-9","volume":"21","author":"F Zhang","year":"2022","unstructured":"Zhang, F. et al. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia. Nat. Mater. 21, 1324\u20131332 (2022).","journal-title":"Nat. Mater."},{"key":"2982_CR290","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s11095-009-9894-2","volume":"26","author":"JC Sung","year":"2009","unstructured":"Sung, J. C. et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 26, 1847\u20131855 (2009).","journal-title":"Pharm. Res."},{"key":"2982_CR291","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3390\/ph17121628","volume":"17","author":"SE Maloney Norcross","year":"2024","unstructured":"Maloney Norcross, S. E., Levin, L. P. K., Hickey, A. J. & Hill, D. B. Biopolymeric inhalable dry powders for pulmonary drug delivery. Pharmaceuticals 17, 1628 (2024).","journal-title":"Pharmaceuticals"},{"key":"2982_CR292","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1021\/acs.molpharmaceut.5b00118","volume":"12","author":"PG Durham","year":"2015","unstructured":"Durham, P. G. et al. Spray dried aerosol particles of pyrazinoic acid salts for tuberculosis therapy. [Corrected]. Mol. Pharm. 12, 2574\u20132581 (2015).","journal-title":"Mol. Pharm."},{"key":"2982_CR293","first-page":"1115","volume":"11","author":"S Peppe","year":"2024","unstructured":"Peppe, S. et al. Nanoparticle-mediated delivery of deferasirox: a promising strategy against invasive aspergillosis. Bioeng. 11, 1115 (2024).","journal-title":"Bioeng."},{"key":"2982_CR294","doi-asserted-by":"publisher","first-page":"123663","DOI":"10.1016\/j.ijpharm.2023.123663","volume":"649","author":"HA Fayyaz","year":"2024","unstructured":"Fayyaz, H. A. et al. Targeted DPPC\/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment. Int. J. Pharm. 649, 123663 (2024).","journal-title":"Int. J. Pharm."},{"key":"2982_CR295","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/nano12010051","volume":"12","author":"EM Ali","year":"2021","unstructured":"Ali, E. M. & Abdallah, B. M. Effective inhibition of invasive pulmonary aspergillosis by silver nanoparticles biosynthesized with artemisia sieberi leaf extract. Nanomaterials 12, 51 (2021).","journal-title":"Nanomaterials"},{"key":"2982_CR296","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jconrel.2024.07.047","volume":"373","author":"Y Yu","year":"2024","unstructured":"Yu, Y. et al. Cascade-targeting polymeric particles eliminate intracellular C. neoformans in fungal infection therapy. J. Control Release 373, 399\u2013409 (2024).","journal-title":"J. Control Release"},{"key":"2982_CR297","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).","journal-title":"Mol. Cancer"},{"key":"2982_CR298","doi-asserted-by":"publisher","first-page":"103553","DOI":"10.1016\/j.jddst.2022.103553","volume":"74","author":"B Wilson","year":"2022","unstructured":"Wilson, B. & Geetha, K. M. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J. Drug Deliv. Sci. Technol. 74, 103553 (2022).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"2982_CR299","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00751-6","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 8, 156 (2023).","journal-title":"NPJ Vaccines"},{"key":"2982_CR300","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.ebiom.2022.103841","volume":"76","author":"A Alu","year":"2022","unstructured":"Alu, A. et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 76, 103841 (2022).","journal-title":"EBioMedicine"},{"key":"2982_CR301","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38066-8","volume":"14","author":"H Lei","year":"2023","unstructured":"Lei, H. et al. Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants. Nat. Commun. 14, 2678 (2023).","journal-title":"Nat. Commun."},{"key":"2982_CR302","doi-asserted-by":"publisher","first-page":"1336906","DOI":"10.3389\/fimmu.2024.1336906","volume":"15","author":"BZ Igyarto","year":"2024","unstructured":"Igyarto, B. Z. & Qin, Z. The mRNA-LNP vaccines\u2014the good, the bad and the ugly? Front. Immunol. 15, 1336906 (2024).","journal-title":"Front. Immunol."},{"key":"2982_CR303","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","volume":"29","author":"A Idris","year":"2021","unstructured":"Idris, A. et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol. Ther. 29, 2219\u20132226 (2021).","journal-title":"Mol. Ther."},{"key":"2982_CR304","doi-asserted-by":"publisher","first-page":"e2314747121","DOI":"10.1073\/pnas.2314747121","volume":"121","author":"G Zhao","year":"2024","unstructured":"Zhao, G. et al. Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery. Proc. Natl. Acad. Sci. USA 121, e2314747121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2982_CR305","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41565-021-00923-2","volume":"16","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. Nat. Nanotechnol. 16, 942\u2013951 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR306","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122721","volume":"312","author":"L Martin-Faivre","year":"2025","unstructured":"Martin-Faivre, L. et al. Pulmonary delivery of silver nanoparticles prevents influenza infection by recruiting and activating lymphoid cells. Biomaterials 312, 122721 (2025).","journal-title":"Biomaterials"},{"key":"2982_CR307","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-2600(24)00339-4","volume":"13","author":"MM De Oca","year":"2025","unstructured":"De Oca, M. M. et al. The global burden of COPD: epidemiology and effect of prevention strategies. Lancet Respir. Med. 13, 709\u2013724 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2982_CR308","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMe1515508","volume":"374","author":"LM Fabbri","year":"2016","unstructured":"Fabbri, L. M. Smoking, not COPD, as the disease. N. Engl. J. Med. 374, 1885\u20131886 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2982_CR309","doi-asserted-by":"publisher","first-page":"210262","DOI":"10.1183\/16000617.0262-2021","volume":"31","author":"M Miravitlles","year":"2022","unstructured":"Miravitlles, M. et al. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews. Eur. Respir. Rev. 31, 210262 (2022).","journal-title":"Eur. Respir. Rev."},{"key":"2982_CR310","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(04)15650-X","volume":"363","author":"PJ Barnes","year":"2004","unstructured":"Barnes, P. J., Ito, K. & Adcock, I. M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363, 731\u2013733 (2004).","journal-title":"Lancet"},{"key":"2982_CR311","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404615","volume":"15","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Inflammation mechanism and research progress of COPD. Front. Immunol. 15, 1404615 (2024).","journal-title":"Front. Immunol."},{"key":"2982_CR312","doi-asserted-by":"publisher","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","volume":"54","author":"C Brightling","year":"2019","unstructured":"Brightling, C. & Greening, N. Airway inflammation in COPD: progress to precision medicine. Eur. Respir. J. 54, 1900651 (2019).","journal-title":"Eur. Respir. J."},{"key":"2982_CR313","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4102\/safp.v62i1.5198","volume":"62","author":"EM Irusen","year":"2020","unstructured":"Irusen, E. M. & Malange, T. Pharmacotherapy of chronic obstructive pulmonary disease: therapeutic considerations with a focus on inhaled corticosteroids. S. Afr. Fam. Pract. 62, e1\u2013e6 (2020).","journal-title":"S. Afr. Fam. Pract."},{"key":"2982_CR314","first-page":"CD002991","volume":"3","author":"IA Yang","year":"2023","unstructured":"Yang, I. A. et al. Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 3, CD002991 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2982_CR315","first-page":"CD002309","volume":"9","author":"J Chong","year":"2017","unstructured":"Chong, J., Leung, B. & Poole, P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 9, CD002309 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2982_CR316","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4046\/trd.2016.79.4.241","volume":"79","author":"KM Beeh","year":"2016","unstructured":"Beeh, K. M. The role of bronchodilators in preventing exacerbations of chronic obstructive pulmonary disease. Tuberc. Respir. Dis. 79, 241\u2013247 (2016).","journal-title":"Tuberc. Respir. Dis."},{"key":"2982_CR317","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.2147\/COPD.S185975","volume":"13","author":"L Vanfleteren","year":"2018","unstructured":"Vanfleteren, L. et al. Triple therapy (ICS\/LABA\/LAMA) in COPD: time for a reappraisal. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 3971\u20133981 (2018).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"2982_CR318","doi-asserted-by":"publisher","first-page":"125740","DOI":"10.1016\/j.ijpharm.2025.125740","volume":"678","author":"WH Chen","year":"2025","unstructured":"Chen, W. H., Chen, C. H. & Chang, M. H. Exploring nanoparticles in lungs under COPD conditions for nanospray drug flow and deposition: CFD simulations and AI predictions. Int. J. Pharm. 678, 125740 (2025).","journal-title":"Int. J. Pharm."},{"key":"2982_CR319","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1165\/rcmb.2017-0200TR","volume":"58","author":"M Aghapour","year":"2018","unstructured":"Aghapour, M. et al. Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: role of cigarette smoke exposure. Am. J. Respir. Cell Mol. Biol. 58, 157\u2013169 (2018).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR320","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.2147\/COPD.S266394","volume":"16","author":"JR Baker","year":"2021","unstructured":"Baker, J. R. & Donnelly, L. E. Leukocyte function in COPD: clinical relevance and potential for drug therapy. Int. J. Chron. Obstruct. Pulmon. Dis. 16, 2227\u20132242 (2021).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"2982_CR321","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijpharm.2018.04.030","volume":"545","author":"V De Leo","year":"2018","unstructured":"De Leo, V. et al. Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. Int. J. Pharm. 545, 378\u2013388 (2018).","journal-title":"Int. J. Pharm."},{"key":"2982_CR322","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.nano.2016.06.008","volume":"12","author":"N Vij","year":"2016","unstructured":"Vij, N. et al. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases. Nanomedicine 12, 2415\u20132427 (2016).","journal-title":"Nanomedicine"},{"key":"2982_CR323","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118524","volume":"569","author":"A Mohamed","year":"2019","unstructured":"Mohamed, A. et al. Pulmonary delivery of nanocomposite microparticles (NCMPs) incorporating miR-146a for treatment of COPD. Int. J. Pharm. 569, 118524 (2019).","journal-title":"Int. J. Pharm."},{"key":"2982_CR324","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/hmg\/ddx167","volume":"26","author":"G Hayashi","year":"2017","unstructured":"Hayashi, G. et al. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum. Mol. Genet. 26, 2864\u20132873 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"2982_CR325","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1039\/C5ME00004A","volume":"1","author":"P Muralidharan","year":"2016","unstructured":"Muralidharan, P., Hayes, D. Jr., Black, S. M. & Mansour, H. M. Microparticulate\/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2\/Keap-1 pathway. Mol. Syst. Des. Eng. 1, 48\u201365 (2016).","journal-title":"Mol. Syst. Des. Eng."},{"key":"2982_CR326","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/nu15041019","volume":"15","author":"G De Rubis","year":"2023","unstructured":"De Rubis, G. et al. Agarwood oil nanoemulsion attenuates cigarette smoke-induced inflammation and oxidative stress markers in BCi-NS1.1 airway epithelial cells. Nutrients 15, 1019 (2023).","journal-title":"Nutrients"},{"key":"2982_CR327","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/antiox11050873","volume":"11","author":"KR Paudel","year":"2022","unstructured":"Paudel, K. R. et al. Attenuation of cigarette-smoke-induced oxidative stress, senescence, and inflammation by berberine-loaded liquid crystalline nanoparticles: in vitro study in 16HBE and RAW264.7 cells. Antioxidants 11, 873 (2022).","journal-title":"Antioxidants"},{"key":"2982_CR328","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10715762.2019.1696965","volume":"54","author":"K Chikuma","year":"2020","unstructured":"Chikuma, K. et al. The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD. Free Radic. Res. 54, 829\u2013840 (2020).","journal-title":"Free Radic. Res."},{"key":"2982_CR329","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd7904","volume":"10","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease. Sci. Adv. 10, eabd7904 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR330","doi-asserted-by":"publisher","first-page":"20568","DOI":"10.1002\/anie.202008379","volume":"59","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Mediated drug release from nanovehicles by black phosphorus quantum dots for efficient therapy of chronic obstructive pulmonary disease. Angew. Chem. Int. Ed. Engl. 59, 20568\u201320576 (2020).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2982_CR331","doi-asserted-by":"publisher","first-page":"113648","DOI":"10.1016\/j.jconrel.2025.113648","volume":"381","author":"Q Yu","year":"2025","unstructured":"Yu, Q. et al. Inhalable neutrophil-mimicking nanoparticles for chronic obstructive pulmonary disease treatment. J. Control Release 381, 113648 (2025).","journal-title":"J. Control Release"},{"key":"2982_CR332","doi-asserted-by":"publisher","first-page":"220261","DOI":"10.1183\/20734735.0261-2022","volume":"18","author":"BD Kent","year":"2022","unstructured":"Kent, B. D. Pulmonary vascular disease for the general respiratory clinician. Breathe 18, 220261 (2022).","journal-title":"Breathe"},{"key":"2982_CR333","doi-asserted-by":"publisher","first-page":"e029024","DOI":"10.1161\/JAHA.122.029024","volume":"12","author":"BA Maron","year":"2023","unstructured":"Maron, B. A. Revised definition of pulmonary hypertension and approach to management: a clinical primer. J. Am. Heart Assoc. 12, e029024 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"2982_CR334","doi-asserted-by":"publisher","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","volume":"64","author":"G Kovacs","year":"2024","unstructured":"Kovacs, G. et al. Definition, classification and diagnosis of pulmonary hypertension. Eur. Respir. J. 64, 2401324 (2024).","journal-title":"Eur. Respir. J."},{"key":"2982_CR335","doi-asserted-by":"publisher","first-page":"2300449","DOI":"10.1183\/13993003.00449-2023","volume":"62","author":"D Luijten","year":"2023","unstructured":"Luijten, D. et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis. Eur. Respir. J. 62, 2300449 (2023).","journal-title":"Eur. Respir. J."},{"key":"2982_CR336","doi-asserted-by":"publisher","first-page":"230156","DOI":"10.1183\/16000617.0156-2023","volume":"33","author":"B Lechartier","year":"2024","unstructured":"Lechartier, B. et al. Pulmonary veno-occlusive disease: illustrative cases and literature review. Eur. Respir. Rev. 33, 230156 (2024).","journal-title":"Eur. Respir. Rev."},{"key":"2982_CR337","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1152\/physrev.00053.2021","volume":"103","author":"MJ Davis","year":"2023","unstructured":"Davis, M. J., Earley, S., Li, Y. S. & Chien, S. Vascular mechanotransduction. Physiol. Rev. 103, 1247\u20131421 (2023).","journal-title":"Physiol. Rev."},{"key":"2982_CR338","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478\u20131490 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2982_CR339","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.651","volume":"5","author":"X Wang","year":"2024","unstructured":"Wang, X. & He, B. Endothelial dysfunction: molecular mechanisms and clinical implications. MedComm 5, e651 (2024).","journal-title":"MedComm"},{"key":"2982_CR340","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/ars.2020.8169","volume":"34","author":"A Gorelova","year":"2021","unstructured":"Gorelova, A., Berman, M. & Al Ghouleh, I. Endothelial-to-mesenchymal transition in pulmonary arterial hypertension. Antioxid. Redox Signal. 34, 891\u2013914 (2021).","journal-title":"Antioxid. Redox Signal."},{"key":"2982_CR341","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1161\/CIRCRESAHA.122.320084","volume":"130","author":"MA Aldred","year":"2022","unstructured":"Aldred, M. A., Morrell, N. W. & Guignabert, C. New mutations and pathogenesis of pulmonary hypertension: progress and puzzles in disease pathogenesis. Circ. Res. 130, 1365\u20131381 (2022).","journal-title":"Circ. Res."},{"key":"2982_CR342","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1165\/rcmb.2023-0355OC","volume":"72","author":"X Zou","year":"2025","unstructured":"Zou, X. et al. SOX17 prevents endothelial-mesenchymal transition of pulmonary arterial endothelial cells in pulmonary hypertension through mediating TGF-beta\/Smad2\/3 signaling. Am. J. Respir. Cell Mol. Biol. 72, 364\u2013379 (2025).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR343","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1161\/CIRCULATIONAHA.121.053980","volume":"144","author":"F Sun","year":"2021","unstructured":"Sun, F. et al. Nanoparticle delivery of STAT3 alleviates pulmonary hypertension in a mouse model of alveolar capillary dysplasia. Circulation 144, 539\u2013555 (2021).","journal-title":"Circulation"},{"key":"2982_CR344","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43039-y","volume":"14","author":"S Isobe","year":"2023","unstructured":"Isobe, S. et al. Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension. Nat. Commun. 14, 7578 (2023).","journal-title":"Nat. Commun."},{"key":"2982_CR345","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/1389202916666150122223252","volume":"16","author":"AV Dharmadhikari","year":"2015","unstructured":"Dharmadhikari, A. V., Szafranski, P., Kalinichenko, V. V. & Stankiewicz, P. Genomic and epigenetic complexity of the FOXF1 locus in 16q24.1: implications for development and disease. Curr. Genomics. 16, 107\u2013116 (2015).","journal-title":"Curr. Genomics."},{"key":"2982_CR346","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1164\/rccm.201812-2312OC","volume":"200","author":"X Ren","year":"2019","unstructured":"Ren, X. et al. Postnatal alveologenesis depends on FOXF1 signaling in c-KIT(+) endothelial progenitor cells. Am. J. Respir. Crit. Care Med. 200, 1164\u20131176 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR347","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1128\/MCB.01736-06","volume":"27","author":"D Malin","year":"2007","unstructured":"Malin, D. et al. Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression. Mol. Cell Biol. 27, 2486\u20132498 (2007).","journal-title":"Mol. Cell Biol."},{"key":"2982_CR348","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.123.066430","volume":"150","author":"H Shen","year":"2024","unstructured":"Shen, H. et al. BRCC3 regulation of ALK2 in vascular smooth muscle cells: implication in pulmonary hypertension. Circulation 150, 132\u2013150 (2024).","journal-title":"Circulation"},{"key":"2982_CR349","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202401909","volume":"13","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. A non-metallic nanozyme ameliorates pulmonary hypertension through inhibiting ROS\/TGF-beta1 signaling. Adv. Health. Mater. 13, e2401909 (2024).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR350","doi-asserted-by":"crossref","unstructured":"Zhao, H. et al. Hydrogen-generated metal-organic framework nanoparticles for ameliorated pulmonary hypertension by ROS scavenging, hydrogen anti-inflammation, and reducing DNA damage. Mater. Today Nano 31, 100652 (2025).","DOI":"10.1016\/j.mtnano.2025.100652"},{"key":"2982_CR351","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1016\/j.apsb.2025.07.004","volume":"15","author":"Y Cao","year":"2025","unstructured":"Cao, Y. et al. Targeted delivery of BMPR2 mRNA attenuates pulmonary arterial hypertension by reversing pulmonary vascular remodeling. Acta Pharm Sin. B 15, 5416\u20135430 (2025).","journal-title":"Acta Pharm Sin. B"},{"key":"2982_CR352","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.redox.2022.102524","volume":"58","author":"D Cai","year":"2022","unstructured":"Cai, D. & Chen, S. Y. Nanoparticle endothelial delivery of PGC-1alpha attenuates hypoxia-induced pulmonary hypertension by attenuating EndoMT-caused vascular wall remodeling. Redox Biol. 58, 102524 (2022).","journal-title":"Redox Biol."},{"key":"2982_CR353","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400113","volume":"13","author":"M Li","year":"2024","unstructured":"Li, M. et al. Active anchoring stimuli-responsive nano-craft to relieve pulmonary vasoconstriction by targeting smooth muscle cell for hypoxic pulmonary hypertension treatment. Adv. Health. Mater. 13, e2400113 (2024).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR354","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1021\/acsnano.2c12190","volume":"17","author":"R Yuan","year":"2023","unstructured":"Yuan, R. et al. Biomimetic nanoparticle-mediated target delivery of hypoxia-responsive plasmid of angiotensin-converting enzyme 2 to reverse hypoxic pulmonary hypertension. ACS Nano. 17, 8204\u20138222 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR355","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400476","volume":"11","author":"L Ning","year":"2024","unstructured":"Ning, L. et al. Targeted rapamycin delivery via magnetic nanoparticles to address stenosis in a 3D bioprinted in vitro model of pulmonary veins. Adv. Sci. 11, e2400476 (2024).","journal-title":"Adv. Sci."},{"key":"2982_CR356","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/pharmaceutics14020302","volume":"14","author":"AJ Plaunt","year":"2022","unstructured":"Plaunt, A. J. et al. Strategies to overcome biological barriers associated with pulmonary drug delivery. Pharmaceutics 14, 302 (2022).","journal-title":"Pharmaceutics"},{"key":"2982_CR357","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1007\/s12325-022-02296-x","volume":"39","author":"FA Ismat","year":"2022","unstructured":"Ismat, F. A. et al. Safety, tolerability, and pharmacokinetics of treprostinil palmitil inhalation powder for pulmonary hypertension: a phase 1, randomized, double-blind, single- and multiple-dose study. Adv. Ther. 39, 5144\u20135157 (2022).","journal-title":"Adv. Ther."},{"key":"2982_CR358","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ame2.12180","volume":"4","author":"Q Chen","year":"2021","unstructured":"Chen, Q., Shen, Y. & Zheng, J. A review of cystic fibrosis: basic and clinical aspects. Anim. Model Exp. Med. 4, 220\u2013232 (2021).","journal-title":"Anim. Model Exp. Med."},{"key":"2982_CR359","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1126\/science.ade2216","volume":"378","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk, K. & Chen, J. Molecular structures reveal synergistic rescue of Delta508 CFTR by Trikafta modulators. Science 378, 284\u2013290 (2022).","journal-title":"Science"},{"key":"2982_CR360","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2021.23280","volume":"327","author":"TM Endres","year":"2022","unstructured":"Endres, T. M. & Konstan, M. W. What is cystic fibrosis? JAMA 327, 191 (2022).","journal-title":"JAMA"},{"key":"2982_CR361","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","volume":"402","author":"SY Graeber","year":"2023","unstructured":"Graeber, S. Y. & Mall, M. A. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet 402, 1185\u20131198 (2023).","journal-title":"Lancet"},{"key":"2982_CR362","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jcf.2022.12.016","volume":"22","author":"NE Allaire","year":"2023","unstructured":"Allaire, N. E. et al. Gene, RNA, and ASO-based therapeutic approaches in cystic fibrosis. J. Cyst. Fibros. 22, S39\u2013S44 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"2982_CR363","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1089\/hum.2022.172","volume":"33","author":"G McLachlan","year":"2022","unstructured":"McLachlan, G. et al. Progress in respiratory gene therapy. Hum. Gene Ther. 33, 893\u2013912 (2022).","journal-title":"Hum. Gene Ther."},{"key":"2982_CR364","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","volume":"26","author":"E Robinson","year":"2018","unstructured":"Robinson, E. et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 26, 2034\u20132046 (2018).","journal-title":"Mol. Ther."},{"key":"2982_CR365","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202304525","volume":"13","author":"B Tafech","year":"2024","unstructured":"Tafech, B. et al. Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions. Adv. Health. Mater. 13, e2304525 (2024).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR366","doi-asserted-by":"publisher","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","volume":"16","author":"J Kim","year":"2022","unstructured":"Kim, J. et al. Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation. ACS Nano. 16, 14792\u201314806 (2022).","journal-title":"ACS Nano."},{"key":"2982_CR367","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1021\/acsami.1c14975","volume":"14","author":"G Conte","year":"2022","unstructured":"Conte, G. et al. Hybrid lipid\/polymer nanoparticles to tackle the cystic fibrosis mucus barrier in sirna delivery to the lungs: does PEGylation make the difference? ACS Appl Mater. Interfaces 14, 7565\u20137578 (2022).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"2982_CR368","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","volume":"74","author":"S Anderson","year":"2022","unstructured":"Anderson, S. et al. Inhaled medicines: past, present, and future. Pharm. Rev. 74, 48\u2013118 (2022).","journal-title":"Pharm. Rev."},{"key":"2982_CR369","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41565-018-0358-x","volume":"14","author":"S Guan","year":"2019","unstructured":"Guan, S. et al. Self-assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat. Nanotechnol. 14, 287\u2013297 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR370","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo0522","volume":"8","author":"AS Piotrowski-Daspit","year":"2022","unstructured":"Piotrowski-Daspit, A. S. et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Sci. Adv. 8, eabo0522 (2022).","journal-title":"Sci. Adv."},{"key":"2982_CR371","doi-asserted-by":"publisher","first-page":"637948","DOI":"10.3389\/fimmu.2021.637948","volume":"12","author":"B Leon","year":"2021","unstructured":"Leon, B. & Ballesteros-Tato, A. Modulating Th2 cell immunity for the treatment of asthma. Front. Immunol. 12, 637948 (2021).","journal-title":"Front. Immunol."},{"key":"2982_CR372","doi-asserted-by":"publisher","first-page":"1149203","DOI":"10.3389\/fimmu.2023.1149203","volume":"14","author":"T Ji","year":"2023","unstructured":"Ji, T. & Li, H. T-helper cells and their cytokines in pathogenesis and treatment of asthma. Front. Immunol. 14, 1149203 (2023).","journal-title":"Front. Immunol."},{"key":"2982_CR373","doi-asserted-by":"publisher","first-page":"e20221094","DOI":"10.1084\/jem.20221094","volume":"220","author":"JA Harker","year":"2023","unstructured":"Harker, J. A. & Lloyd, C. M. T helper 2 cells in asthma. J. Exp. Med. 220, e20221094 (2023).","journal-title":"J. Exp. Med."},{"key":"2982_CR374","doi-asserted-by":"publisher","first-page":"10451","DOI":"10.3390\/ijms241310451","volume":"24","author":"RD Britt Jr.","year":"2023","unstructured":"Britt, R. D. Jr., Ruwanpathirana, A., Ford, M. L. & Lewis, B. W. Macrophages orchestrate airway inflammation, remodeling, and resolution in asthma. Int. J. Mol. Sci. 24, 10451 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR375","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/ACI.0000000000000703","volume":"21","author":"RC Murphy","year":"2021","unstructured":"Murphy, R. C. & Hallstrand, T. S. Exploring the origin and regulatory role of mast cells in asthma. Curr. Opin. Allergy Clin. Immunol. 21, 71\u201378 (2021).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2982_CR376","doi-asserted-by":"publisher","first-page":"3743048","DOI":"10.1155\/2017\/3743048","volume":"2017","author":"H Gao","year":"2017","unstructured":"Gao, H., Ying, S. & Dai, Y. Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target. J. Immunol. Res. 2017, 3743048 (2017).","journal-title":"J. Immunol. Res."},{"key":"2982_CR377","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101483","volume":"69","author":"VH Patel","year":"2023","unstructured":"Patel, V. H. et al. Current limitations and recent advances in the management of asthma. Dis. Mon. 69, 101483 (2023).","journal-title":"Dis. Mon."},{"key":"2982_CR378","doi-asserted-by":"publisher","first-page":"190096","DOI":"10.1183\/16000617.0096-2019","volume":"28","author":"R Wadhwa","year":"2019","unstructured":"Wadhwa, R. et al. Cellular mechanisms underlying steroid-resistant asthma. Eur. Respir. Rev. 28, 190096 (2019).","journal-title":"Eur. Respir. Rev."},{"key":"2982_CR379","doi-asserted-by":"publisher","first-page":"23606","DOI":"10.1021\/acsnano.5c01226","volume":"19","author":"EK An","year":"2025","unstructured":"An, E. K. et al. Tolerogenic dendritic cell- and M2 macrophage polarization-inducible hybrid nanoparticles alleviate asthma in mice. ACS Nano. 19, 23606\u201323619 (2025).","journal-title":"ACS Nano."},{"key":"2982_CR380","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jconrel.2021.08.024","volume":"338","author":"W Pei","year":"2021","unstructured":"Pei, W. et al. Exosome membrane-modified M2 macrophages targeted nanomedicine: treatment for allergic asthma. J. Control Release 338, 253\u2013267 (2021).","journal-title":"J. Control Release"},{"key":"2982_CR381","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jconrel.2022.10.020","volume":"352","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. J. Control Release 352, 422\u2013437 (2022).","journal-title":"J. Control Release"},{"key":"2982_CR382","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3390\/ijms23031622","volume":"23","author":"SH Kang","year":"2022","unstructured":"Kang, S. H. et al. Interactions of nanoparticles with macrophages and feasibility of drug delivery for asthma. Int. J. Mol. Sci. 23, 1622 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR383","doi-asserted-by":"publisher","first-page":"eaay7973","DOI":"10.1126\/sciadv.aay7973","volume":"6","author":"AL da Silva","year":"2020","unstructured":"da Silva, A. L. et al. Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma. Sci. Adv. 6, eaay7973 (2020).","journal-title":"Sci. Adv."},{"key":"2982_CR384","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2024.01.044","volume":"367","author":"Y Yu","year":"2024","unstructured":"Yu, Y., Ni, M., Zheng, Y. & Huang, Y. Airway epithelial-targeted nanoparticle reverses asthma in inhalation therapy. J. Control Release 367, 223\u2013234 (2024).","journal-title":"J. Control Release"},{"key":"2982_CR385","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525\u2013533 (2023).","journal-title":"Nature"},{"key":"2982_CR386","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms26052049","volume":"26","author":"B Smolarz","year":"2025","unstructured":"Smolarz, B. et al. Lung cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature). Int. J. Mol. Sci. 26, 2049 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR387","doi-asserted-by":"publisher","first-page":"548","DOI":"10.21147\/j.issn.1000-9604.2021.05.02","volume":"33","author":"ES Cheng","year":"2021","unstructured":"Cheng, E. S., Weber, M., Steinberg, J. & Yu, X. Q. Lung cancer risk in never-smokers: an overview of environmental and genetic factors. Chin. J. Cancer Res. 33, 548\u2013562 (2021).","journal-title":"Chin. J. Cancer Res."},{"key":"2982_CR388","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2020.110440","volume":"196","author":"M Ciabattini","year":"2021","unstructured":"Ciabattini, M. et al. Systematic review and meta-analysis of recent high-quality studies on exposure to particulate matter and risk of lung cancer. Environ. Res. 196, 110440 (2021).","journal-title":"Environ. Res."},{"key":"2982_CR389","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan, A. C. & Tan, D. S. W. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J. Clin. Oncol. 40, 611\u2013625 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2982_CR390","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","volume":"28","author":"Y Jin","year":"2022","unstructured":"Jin, Y. et al. Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer. Clin. Cancer Res. 28, 526\u2013539 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2982_CR391","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jtho.2022.11.019","volume":"18","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. PTEN loss expands the histopathologic diversity and lineage plasticity of lung cancers initiated by Rb1\/Trp53 deletion. J. Thorac. Oncol. 18, 324\u2013338 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2982_CR392","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1158\/1078-0432.CCR-15-2377","volume":"22","author":"AJ Redig","year":"2016","unstructured":"Redig, A. J. et al. Clinical and molecular characteristics of NF1-mutant lung cancer. Clin. Cancer Res. 22, 3148\u20133156 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2982_CR393","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1172\/JCI82720","volume":"126","author":"MD Edmonds","year":"2016","unstructured":"Edmonds, M. D. et al. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J. Clin. Invest. 126, 349\u2013364 (2016).","journal-title":"J. Clin. Invest."},{"key":"2982_CR394","doi-asserted-by":"publisher","first-page":"1222059","DOI":"10.3389\/fgene.2023.1222059","volume":"14","author":"D Liu","year":"2023","unstructured":"Liu, D., Lu, X., Huang, W. & Zhuang, W. Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance. Front. Genet. 14, 1222059 (2023).","journal-title":"Front. Genet."},{"key":"2982_CR395","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-17-3597","volume":"24","author":"S Kitajima","year":"2018","unstructured":"Kitajima, S. & Barbie, D. A. RASA1\/NF1-mutant lung cancer: racing to the clinic? Clin. Cancer Res. 24, 1243\u20131245 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2982_CR396","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"2982_CR397","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jtho.2024.09.1423","volume":"19","author":"M Itchins","year":"2024","unstructured":"Itchins, M. & Tan, A. C. Defining the pathway to precision therapies for squamous lung cancers. J. Thorac. Oncol. 19, 1591\u20131593 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"2982_CR398","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamasurg.2022.6826","volume":"158","author":"BT Heiden","year":"2023","unstructured":"Heiden, B. T. et al. Association between surgical quality metric adherence and overall survival among us veterans with early-stage non-small cell lung cancer. JAMA Surg. 158, 293\u2013301 (2023).","journal-title":"JAMA Surg."},{"key":"2982_CR399","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","volume":"18","author":"JE Chaft","year":"2021","unstructured":"Chaft, J. E. et al. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat. Rev. Clin. Oncol. 18, 547\u2013557 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2982_CR400","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935\u20131948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2982_CR401","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.3747\/co.26.4481","volume":"26","author":"A Sun","year":"2019","unstructured":"Sun, A. et al. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Curr. Oncol. 26, e372\u2013e384 (2019).","journal-title":"Curr. Oncol."},{"key":"2982_CR402","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer, J. R. et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J. Clin. Oncol. 41, 1200\u20131212 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2982_CR403","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog, B. H., Devarakonda, S. & Govindan, R. Overcoming chemotherapy resistance in SCLC. J. Thorac. Oncol. 16, 2002\u20132015 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2982_CR404","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/bioengineering12090968","volume":"12","author":"Z Deng","year":"2025","unstructured":"Deng, Z. et al. Nanoparticle-based delivery systems for synergistic therapy in lung cancers. Bioengineering 12, 968 (2025).","journal-title":"Bioengineering"},{"key":"2982_CR405","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31926-9","volume":"13","author":"M Reda","year":"2022","unstructured":"Reda, M. et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat. Commun. 13, 4261 (2022).","journal-title":"Nat. Commun."},{"key":"2982_CR406","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi2046","volume":"10","author":"T Saha","year":"2024","unstructured":"Saha, T. et al. Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer. Sci. Adv. 10, eadi2046 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR407","doi-asserted-by":"crossref","unstructured":"Jin, K. et al. RNA-micelles as self-assembling structures for efficient co-delivery of synergistic siRNA and nucleoside analogues to treat CRC lung metastasis. Adv. Funct. Mater. e21863 (2026).","DOI":"10.1002\/adfm.202521863"},{"key":"2982_CR408","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/ijms25021046","volume":"25","author":"T Gonzalez","year":"2024","unstructured":"Gonzalez, T., Muminovic, M., Nano, O. & Vulfovich, M. Folate receptor alpha-A novel approach to cancer therapy. Int. J. Mol. Sci. 25, 1046 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2982_CR409","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.phymed.2018.09.013","volume":"53","author":"P Parashar","year":"2019","unstructured":"Parashar, P. et al. A synergistic approach for management of lung carcinoma through folic acid functionalized co-therapy of capsaicin and gefitinib nanoparticles: enhanced apoptosis and metalloproteinase-9 down-regulation. Phytomedicine 53, 107\u2013123 (2019).","journal-title":"Phytomedicine"},{"key":"2982_CR410","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02939-3","volume":"11","author":"C Gai","year":"2020","unstructured":"Gai, C. et al. MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p\/NRF2 axis in non-small cell lung cancer cells. Cell Death Dis. 11, 751 (2020).","journal-title":"Cell Death Dis."},{"key":"2982_CR411","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.actbio.2021.02.044","volume":"125","author":"X Wang","year":"2021","unstructured":"Wang, X., Cheng, R. & Zhong, Z. Facile fabrication of robust, hyaluronic acid-surfaced and disulfide-crosslinked PLGA nanoparticles for tumor-targeted and reduction-triggered release of docetaxel. Acta Biomater. 125, 280\u2013289 (2021).","journal-title":"Acta Biomater."},{"key":"2982_CR412","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.actbio.2024.07.020","volume":"186","author":"T Tsai","year":"2024","unstructured":"Tsai, T. et al. CD44-hyaluronan mediating endocytosis of iron-platinum alloy nanoparticles induces ferroptotic cell death in mesenchymal-state lung cancer cells with tyrosine kinase inhibitor resistance. Acta Biomater. 186, 396\u2013410 (2024).","journal-title":"Acta Biomater."},{"key":"2982_CR413","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101632","volume":"31","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Chondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis. Mater. Today Bio. 31, 101632 (2025).","journal-title":"Mater. Today Bio."},{"key":"2982_CR414","doi-asserted-by":"publisher","first-page":"9386","DOI":"10.1021\/acsnano.9b04166","volume":"13","author":"H Li","year":"2019","unstructured":"Li, H. et al. Chondroitin sulfate-linked prodrug nanoparticles target the golgi apparatus for cancer metastasis treatment. ACS Nano. 13, 9386\u20139396 (2019).","journal-title":"ACS Nano."},{"key":"2982_CR415","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.7150\/thno.39816","volume":"9","author":"OB Garbuzenko","year":"2019","unstructured":"Garbuzenko, O. B. et al. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics 9, 8362\u20138376 (2019).","journal-title":"Theranostics"},{"key":"2982_CR416","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58312-5","volume":"16","author":"X Fu","year":"2025","unstructured":"Fu, X. et al. Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer. Nat. Commun. 16, 3336 (2025).","journal-title":"Nat. Commun."},{"key":"2982_CR417","doi-asserted-by":"publisher","first-page":"31273","DOI":"10.1021\/acsami.3c05007","volume":"15","author":"G Zhao","year":"2023","unstructured":"Zhao, G. et al. Inhalable siRNA nanoparticles for enhanced tumor-targeting treatment of KRAS-mutant non-small-cell lung cancer. ACS Appl Mater. Interfaces 15, 31273\u201331284 (2023).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"2982_CR418","doi-asserted-by":"publisher","first-page":"123004","DOI":"10.1016\/j.biomaterials.2024.123004","volume":"316","author":"Y Jeong","year":"2025","unstructured":"Jeong, Y., Shim, Y. S., Jo, Y. K. & Cha, H. J. Redox-activatable inhalable mucoadhesive proteinic nanotherapeutics for targeted treatment of lung cancer. Biomaterials 316, 123004 (2025).","journal-title":"Biomaterials"},{"key":"2982_CR419","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122955","volume":"315","author":"D Ge","year":"2025","unstructured":"Ge, D. et al. Pulmonary delivery of dual-targeted nanoparticles improves tumor accumulation and cancer cell targeting by restricting macrophage interception in orthotopic lung tumors. Biomaterials 315, 122955 (2025).","journal-title":"Biomaterials"},{"key":"2982_CR420","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202100590","volume":"10","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Tumor associated macrophages and TAMs-based anti-tumor nanomedicines. Adv. Health. Mater. 10, e2100590 (2021).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR421","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1021\/acsami.9b21381","volume":"12","author":"MV Novoselova","year":"2020","unstructured":"Novoselova, M. V. et al. Biodegradable polymeric multilayer capsules for therapy of lung cancer. ACS Appl Mater. Interfaces 12, 5610\u20135623 (2020).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"2982_CR422","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41392-020-0115-0","volume":"5","author":"Y Tie","year":"2020","unstructured":"Tie, Y. et al. Targeting folate receptor beta positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex. Signal Transduct. Target Ther. 5, 6 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2982_CR423","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2020.12.011","volume":"330","author":"YI Park","year":"2021","unstructured":"Park, Y. I. et al. pH-sensitive multi-drug liposomes targeting folate receptor beta for efficient treatment of non-small cell lung cancer. J. Control Release 330, 1\u201314 (2021).","journal-title":"J. Control Release"},{"key":"2982_CR424","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp7561","volume":"10","author":"A Rong","year":"2024","unstructured":"Rong, A. et al. Respiratory delivery of single low-dose nebulized PFCE-C25 NEs for lymphatic transport and durable stimulation of antitumor immunity in lung cancer. Sci. Adv. 10, eadp7561 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR425","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114061","volume":"386","author":"R Zhang","year":"2025","unstructured":"Zhang, R. et al. Low-dose inhalable amino acid-modified multilamellar nanoparticles activate STING for safe and effective regression of lung metastases. J. Control Release 386, 114061 (2025).","journal-title":"J. Control Release"},{"key":"2982_CR426","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s44321-024-00064-8","volume":"16","author":"F Bian","year":"2024","unstructured":"Bian, F. et al. FOXF1 promotes tumor vessel normalization and prevents lung cancer progression through FZD4. EMBO Mol. Med. 16, 1063\u20131090 (2024).","journal-title":"EMBO Mol. Med."},{"key":"2982_CR427","doi-asserted-by":"publisher","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","volume":"17","author":"D Wei","year":"2023","unstructured":"Wei, D., Sun, Y., Zhu, H. & Fu, Q. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 17, 23223\u201323261 (2023).","journal-title":"ACS Nano."},{"key":"2982_CR428","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202101437","volume":"6","author":"X Jing","year":"2022","unstructured":"Jing, X. et al. The intracellular and extracellular microenvironment of tumor site: the trigger of stimuli-responsive drug delivery systems. Small Methods 6, e2101437 (2022).","journal-title":"Small Methods"},{"key":"2982_CR429","doi-asserted-by":"publisher","first-page":"8212","DOI":"10.1021\/acsnano.4c17899","volume":"19","author":"Q Chen","year":"2025","unstructured":"Chen, Q. et al. Tumor microenvironment-responsive nano-immunomodulators for enhancing chimeric antigen receptor-T cell therapy in lung cancer. ACS Nano. 19, 8212\u20138226 (2025).","journal-title":"ACS Nano."},{"key":"2982_CR430","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp9071","volume":"10","author":"Q Huang","year":"2024","unstructured":"Huang, Q. et al. An \u201cAND\u201d logic gate-based supramolecular therapeutic nanoplatform for combatting drug-resistant non-small cell lung cancer. Sci. Adv. 10, eadp9071 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR431","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/joim.13201","volume":"289","author":"J Sainz de Aja","year":"2021","unstructured":"Sainz de Aja, J., Dost, A. F. M. & Kim, C. F. Alveolar progenitor cells and the origin of lung cancer. J. Intern. Med. 289, 629\u2013635 (2021).","journal-title":"J. Intern. Med."},{"key":"2982_CR432","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2982_CR433","doi-asserted-by":"publisher","first-page":"8115","DOI":"10.1021\/acs.nanolett.3c02193","volume":"23","author":"S Xiao","year":"2023","unstructured":"Xiao, S. et al. Accurate and convenient lung cancer diagnosis through detection of extracellular vesicle membrane proteins via forster resonance energy transfer. Nano Lett. 23, 8115\u20138125 (2023).","journal-title":"Nano Lett."},{"key":"2982_CR434","doi-asserted-by":"publisher","first-page":"104237","DOI":"10.1016\/j.ebiom.2022.104237","volume":"83","author":"Z Deng","year":"2022","unstructured":"Deng, Z., Wu, S., Wang, Y. & Shi, D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine 83, 104237 (2022).","journal-title":"EBioMedicine"},{"key":"2982_CR435","doi-asserted-by":"publisher","first-page":"22037","DOI":"10.1039\/D4NR03704A","volume":"16","author":"MA Benariba","year":"2024","unstructured":"Benariba, M. A. et al. A liposome-based assay for cancer biomarker detection: exploring the correlation between platelet-derived microvesicles and NSCLC-associated miRNAs. Nanoscale 16, 22037\u201322046 (2024).","journal-title":"Nanoscale"},{"key":"2982_CR436","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj9591","volume":"10","author":"Q Zhong","year":"2024","unstructured":"Zhong, Q. et al. Inhalable point-of-care urinary diagnostic platform. Sci. Adv. 10, eadj9591 (2024).","journal-title":"Sci. Adv."},{"key":"2982_CR437","doi-asserted-by":"crossref","unstructured":"Shankar, S. et al. Nanoengineered multiwalled carbon nanotube for lung cancer diagnosis. J. Mol. Struct. 1320, 139629 (2025).","DOI":"10.1016\/j.molstruc.2024.139629"},{"key":"2982_CR438","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.1039\/D4NR00174E","volume":"16","author":"ATT Tran","year":"2024","unstructured":"Tran, A. T. T. et al. Graphene and metal-organic framework hybrids for high-performance sensors for lung cancer biomarker detection supported by machine learning augmentation. Nanoscale 16, 9084\u20139095 (2024).","journal-title":"Nanoscale"},{"key":"2982_CR439","doi-asserted-by":"crossref","unstructured":"Xu, X. et al. A comprehensive review on synergy of multi-modal data and AI technologies in medical diagnosis. Bioengineering 11, 219 (2024).","DOI":"10.3390\/bioengineering11030219"},{"key":"2982_CR440","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins, G. S. et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 385, e078378 (2024).","journal-title":"BMJ"},{"key":"2982_CR441","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1089\/ars.2013.5785","volume":"21","author":"S Wedgwood","year":"2014","unstructured":"Wedgwood, S. & Steinhorn, R. H. Role of reactive oxygen species in neonatal pulmonary vascular disease. Antioxid. Redox Signal. 21, 1926\u20131942 (2014).","journal-title":"Antioxid. Redox Signal."},{"key":"2982_CR442","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1164\/rccm.202207-1332OC","volume":"207","author":"A Pradhan","year":"2023","unstructured":"Pradhan, A. et al. Novel FOXF1-stabilizing compound tanfe stimulates lung angiogenesis in alveolar capillary dysplasia. Am. J. Respir. Crit. Care Med. 207, 1042\u20131054 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR443","doi-asserted-by":"publisher","first-page":"e002112","DOI":"10.1136\/bmjpo-2023-002112","volume":"7","author":"TA Katz","year":"2023","unstructured":"Katz, T. A. et al. Towards a harmonized bronchopulmonary dysplasia definition: a study protocol for an international delphi procedure. BMJ Paediatr. Open. 7, e002112 (2023).","journal-title":"BMJ Paediatr. Open."},{"key":"2982_CR444","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/jamapediatrics.2021.6619","volume":"176","author":"T Abiramalatha","year":"2022","unstructured":"Abiramalatha, T. et al. Interventions to prevent bronchopulmonary dysplasia in preterm neonates: an umbrella review of systematic reviews and meta-analyses. JAMA Pediatr. 176, 502\u2013516 (2022).","journal-title":"JAMA Pediatr."},{"key":"2982_CR445","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-68483-3_1","volume":"228","author":"C Bolte","year":"2018","unstructured":"Bolte, C., Whitsett, J. A., Kalin, T. V. & Kalinichenko, V. V. Transcription factors regulating embryonic development of pulmonary vasculature. Adv. Anat. Embryol. Cell Biol. 228, 1\u201320 (2018).","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"2982_CR446","doi-asserted-by":"publisher","first-page":"L521","DOI":"10.1152\/ajplung.00212.2003","volume":"286","author":"VV Kalinichenko","year":"2004","unstructured":"Kalinichenko, V. V. et al. Foxf1 haploinsufficiency reduces Notch-2 signaling during mouse lung development. Am. J. Physiol. Lung Cell Mol. Physiol. 286, L521\u2013530 (2004).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2982_CR447","doi-asserted-by":"publisher","first-page":"L1253","DOI":"10.1152\/ajplung.00463.2001","volume":"282","author":"VV Kalinichenko","year":"2002","unstructured":"Kalinichenko, V. V. et al. Wild-type levels of the mouse Forkhead Box f1 gene are essential for lung repair. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L1253\u20131265 (2002).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2982_CR448","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1567-133X(03)00010-3","volume":"3","author":"VV Kalinichenko","year":"2003","unstructured":"Kalinichenko, V. V., Gusarova, G. A., Shin, B. & Costa, R. H. The forkhead box F1 transcription factor is expressed in brain and head mesenchyme during mouse embryonic development. Gene Expr. Patterns 3, 153\u2013158 (2003).","journal-title":"Gene Expr. Patterns"},{"key":"2982_CR449","doi-asserted-by":"publisher","first-page":"37908","DOI":"10.1074\/jbc.M506531200","volume":"280","author":"IM Kim","year":"2005","unstructured":"Kim, I. M. et al. Functional characterization of evolutionarily conserved DNA regions in forkhead box f1 gene locus. J. Biol. Chem. 280, 37908\u201337916 (2005).","journal-title":"J. Biol. Chem."},{"key":"2982_CR450","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ydbio.2018.08.011","volume":"443","author":"V Ustiyan","year":"2018","unstructured":"Ustiyan, V. et al. FOXF1 transcription factor promotes lung morphogenesis by inducing cellular proliferation in fetal lung mesenchyme. Dev. Biol. 443, 50\u201363 (2018).","journal-title":"Dev. Biol."},{"key":"2982_CR451","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60371-7","volume":"16","author":"SP Shirazi","year":"2025","unstructured":"Shirazi, S. P. et al. Bronchopulmonary dysplasia with pulmonary hypertension associates with semaphorin signaling loss and functionally decreased FOXF1 expression. Nat. Commun. 16, 5004 (2025).","journal-title":"Nat. Commun."},{"key":"2982_CR452","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1165\/rcmb.2014-0091OC","volume":"52","author":"H Xia","year":"2015","unstructured":"Xia, H. et al. Foxm1 regulates resolution of hyperoxic lung injury in newborns. Am. J. Respir. Cell Mol. Biol. 52, 611\u2013621 (2015).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR453","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1164\/rccm.202003-0758OC","volume":"204","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Generation of pulmonary endothelial progenitor cells for cell-based therapy using interspecies mouse-rat chimeras. Am. J. Respir. Crit. Care Med. 204, 326\u2013338 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR454","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1164\/rccm.201810-1897OC","volume":"200","author":"A Pradhan","year":"2019","unstructured":"Pradhan, A. et al. The S52F FOXF1 mutation inhibits STAT3 signaling and causes alveolar capillary dysplasia. Am. J. Respir. Crit. Care Med. 200, 1045\u20131056 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR455","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1164\/rccm.202210-2015OC","volume":"208","author":"M Guo","year":"2023","unstructured":"Guo, M. et al. Single cell multiomics identifies cells and genetic networks underlying alveolar capillary dysplasia. Am. J. Respir. Crit. Care Med. 208, 709\u2013725 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR456","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1164\/rccm.201903-0495TR","volume":"200","author":"M Vincent","year":"2019","unstructured":"Vincent, M. et al. Clinical, histopathological, and molecular diagnostics in lethal lung developmental disorders. Am. J. Respir. Crit. Care Med. 200, 1093\u20131101 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR457","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12929-024-01088-5","volume":"31","author":"GG Edel","year":"2024","unstructured":"Edel, G. G. et al. The molecular consequences of FOXF1 missense mutations associated with alveolar capillary dysplasia with misalignment of pulmonary veins. J. Biomed. Sci. 31, 100 (2024).","journal-title":"J. Biomed. Sci."},{"key":"2982_CR458","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29746-y","volume":"13","author":"G Wang","year":"2022","unstructured":"Wang, G. et al. Endothelial progenitor cells stimulate neonatal lung angiogenesis through FOXF1-mediated activation of BMP9\/ACVRL1 signaling. Nat. Commun. 13, 2080 (2022).","journal-title":"Nat. Commun."},{"key":"2982_CR459","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-physiol-022724-105226","volume":"87","author":"A Sharma","year":"2025","unstructured":"Sharma, A. & Niethamer, T. K. Specialized pulmonary vascular cells in development and disease. Annu. Rev. Physiol. 87, 229\u2013255 (2025).","journal-title":"Annu. Rev. Physiol."},{"key":"2982_CR460","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1128\/MCB.00355-12","volume":"32","author":"IC Wang","year":"2012","unstructured":"Wang, I. C. et al. Foxm1 mediates cross talk between Kras\/mitogen-activated protein kinase and canonical Wnt pathways during development of respiratory epithelium. Mol. Cell Biol. 32, 3838\u20133850 (2012).","journal-title":"Mol. Cell Biol."},{"key":"2982_CR461","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1165\/rcmb.2008-0044OC","volume":"39","author":"TV Kalin","year":"2008","unstructured":"Kalin, T. V. et al. Pulmonary mastocytosis and enhanced lung inflammation in mice heterozygous null for the Foxf1 gene. Am. J. Respir. Cell Mol. Biol. 39, 390\u2013399 (2008).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2982_CR462","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ydbio.2012.07.028","volume":"370","author":"V Ustiyan","year":"2012","unstructured":"Ustiyan, V. et al. Foxm1 transcription factor is critical for proliferation and differentiation of Clara cells during development of conducting airways. Dev. Biol. 370, 198\u2013212 (2012).","journal-title":"Dev. Biol."},{"key":"2982_CR463","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1164\/rccm.201909-1836OC","volume":"203","author":"B Wen","year":"2021","unstructured":"Wen, B. et al. In vivo generation of lung and thyroid tissues from embryonic stem cells using blastocyst complementation. Am. J. Respir. Crit. Care Med. 203, 471\u2013483 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR464","doi-asserted-by":"publisher","first-page":"e2415824","DOI":"10.1002\/advs.202415824","volume":"12","author":"X Li","year":"2025","unstructured":"Li, X. et al. Endothelial Cpt1a inhibits neonatal hyperoxia-induced pulmonary vascular remodeling by repressing endothelial-mesenchymal transition. Adv. Sci. 12, e2415824 (2025).","journal-title":"Adv. Sci."},{"key":"2982_CR465","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61688-z","volume":"16","author":"Z Zhao","year":"2025","unstructured":"Zhao, Z. et al. Boosting RNA nanotherapeutics with V-ATPase activating non-inflammatory lipid nanoparticles to treat chronic lung injury. Nat. Commun. 16, 6477 (2025).","journal-title":"Nat. Commun."},{"key":"2982_CR466","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1164\/rccm.202401-0161OC","volume":"211","author":"SP Loukogeorgakis","year":"2025","unstructured":"Loukogeorgakis, S. P. et al. Prenatal VEGF nanodelivery reverses congenital diaphragmatic hernia-associated pulmonary abnormalities. Am. J. Respir. Crit. Care Med. 211, 992\u20131006 (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR467","doi-asserted-by":"publisher","first-page":"9994","DOI":"10.1021\/acsnano.2c00128","volume":"16","author":"C Domingues","year":"2022","unstructured":"Domingues, C. et al. Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology. ACS Nano. 16, 9994\u201310041 (2022).","journal-title":"ACS Nano."},{"key":"2982_CR468","doi-asserted-by":"publisher","first-page":"e1805391","DOI":"10.1002\/adma.201805391","volume":"31","author":"L Yan","year":"2019","unstructured":"Yan, L. et al. A safe-by-design strategy towards safer nanomaterials in nanomedicines. Adv. Mater. 31, e1805391 (2019).","journal-title":"Adv. Mater."},{"key":"2982_CR469","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1039\/D1CS00918D","volume":"51","author":"R Ettlinger","year":"2022","unstructured":"Ettlinger, R. et al. Toxicity of metal-organic framework nanoparticles: from essential analyses to potential applications. Chem. Soc. Rev. 51, 464\u2013484 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"2982_CR470","doi-asserted-by":"publisher","first-page":"13039","DOI":"10.2147\/IJN.S554821","volume":"20","author":"Y Herdiana","year":"2025","unstructured":"Herdiana, Y. Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems. Int. J. Nanomed. 20, 13039\u201313053 (2025).","journal-title":"Int. J. Nanomed."},{"key":"2982_CR471","doi-asserted-by":"publisher","first-page":"e2000110","DOI":"10.1002\/adhm.202000110","volume":"9","author":"DM Valcourt","year":"2020","unstructured":"Valcourt, D. M. et al. Best practices for preclinical in vivo testing of cancer nanomedicines. Adv. Health. Mater. 9, e2000110 (2020).","journal-title":"Adv. Health. Mater."},{"key":"2982_CR472","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith, D. E. et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am. J. Respir. Crit. Care Med. 198, 1559\u20131569 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR473","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","volume":"7","author":"CS Haworth","year":"2019","unstructured":"Haworth, C. S. et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir. Med. 7, 213\u2013226 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2982_CR474","doi-asserted-by":"publisher","first-page":"2000110","DOI":"10.1183\/13993003.00110-2020","volume":"56","author":"JD Chalmers","year":"2020","unstructured":"Chalmers, J. D. et al. Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. Eur. Respir. J. 56, 2000110 (2020).","journal-title":"Eur. Respir. J."},{"key":"2982_CR475","doi-asserted-by":"publisher","first-page":"1735885","DOI":"10.3389\/fbioe.2026.1735885","volume":"14","author":"F Stucchi","year":"2026","unstructured":"Stucchi, F., Li, M., Castellano, G. & Cellesi, F. Regulatory framework for polymer-based nanotherapeutics in clinical translation. Front. Bioeng. Biotechnol. 14, 1735885 (2026).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"2982_CR476","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2982_CR477","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2982_CR478","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"2982_CR479","unstructured":"US Food and Drug Administration. Drug Products, Including Biological Products, that Contain Nanomaterials https:\/\/www.fda.gov\/media\/157812\/download (2022)."},{"key":"2982_CR480","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","volume":"19","author":"P Joyce","year":"2024","unstructured":"Joyce, P. et al. A translational framework to DELIVER nanomedicines to the clinic. Nat. Nanotechnol. 19, 1597\u20131611 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"2982_CR481","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S2213-2600(22)00483-0","volume":"11","author":"MCJ Kneyber","year":"2023","unstructured":"Kneyber, M. C. J. et al. Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome. Lancet Respir. Med. 11, 197\u2013212 (2023).","journal-title":"Lancet Respir. Med."},{"key":"2982_CR482","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-2600(18)30344-8","volume":"7","author":"RG Khemani","year":"2019","unstructured":"Khemani, R. G. et al. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study. Lancet Respir. Med. 7, 115\u2013128 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2982_CR483","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1164\/rccm.202310-1926OC","volume":"209","author":"BM Patel","year":"2024","unstructured":"Patel, B. M. et al. Association between age and mortality in pediatric and adult acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 209, 871\u2013878 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2982_CR484","doi-asserted-by":"publisher","first-page":"1216073","DOI":"10.3389\/fped.2023.1216073","volume":"11","author":"L Liu","year":"2023","unstructured":"Liu, L. et al. The perinatal period should be considered in neonatal acute respiratory distress syndrome: comparison of the Montreux definition vs. the second pediatric acute lung injury consensus conference definition. Front. Pediatr. 11, 1216073 (2023).","journal-title":"Front. Pediatr."},{"key":"2982_CR485","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12931-021-01848-z","volume":"22","author":"M Rudolph","year":"2021","unstructured":"Rudolph, M. et al. Performance of acute respiratory distress syndrome definitions in a high acuity paediatric intensive care unit. Respir. Res. 22, 256 (2021).","journal-title":"Respir. Res."},{"key":"2982_CR486","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40005-025-00729-7","volume":"55","author":"KA Shah","year":"2025","unstructured":"Shah, K. A. et al. Current trends in inhaled pharmaceuticals: challenges and opportunities in respiratory infections treatment. J. Pharm. Investig. 55, 191\u2013225 (2025).","journal-title":"J. Pharm. Investig."},{"key":"2982_CR487","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40005-023-00635-w","volume":"54","author":"MS Yang","year":"2024","unstructured":"Yang, M. S., Kang, J. H., Kim, D. W. & Park, C. W. Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery. J. Pharm. Investig. 54, 113\u2013130 (2024).","journal-title":"J. Pharm. Investig."},{"key":"2982_CR488","doi-asserted-by":"publisher","first-page":"299","DOI":"10.7774\/cevr.2025.14.e40","volume":"14","author":"SH Seo","year":"2025","unstructured":"Seo, S. H. & Song, M. K. Advancements and challenges in next-generation mRNA vaccine manufacturing systems. Clin. Exp. Vaccin. Res. 14, 299\u2013307 (2025).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"2982_CR489","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/biom14080904","volume":"14","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Aerosol inhalation of gene delivery therapy for pulmonary diseases. Biomolecules 14, 904 (2024).","journal-title":"Biomolecules"},{"key":"2982_CR490","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.addr.2020.06.001","volume":"168","author":"MYT Chow","year":"2021","unstructured":"Chow, M. Y. T., Chang, R. Y. K. & Chan, H. K. Inhalation delivery technology for genome-editing of respiratory diseases. Adv. Drug Deliv. Rev. 168, 217\u2013228 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2982_CR491","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","volume":"41","author":"B Li","year":"2023","unstructured":"Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410\u20131415 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2982_CR492","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70778","volume":"7","author":"Y Hou","year":"2026","unstructured":"Hou, Y. et al. Acute lung injury: from molecular circuits to system-level therapeutics. MedComm 7, e70778 (2026).","journal-title":"MedComm"},{"key":"2982_CR493","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fmed.2017.00158","volume":"4","author":"S Svenningsen","year":"2017","unstructured":"Svenningsen, S. & Nair, P. Asthma endotypes and an overview of targeted therapy for asthma. Front. Med. 4, 158 (2017).","journal-title":"Front. Med."},{"key":"2982_CR494","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pccm.2026.02.001","volume":"4","author":"H Hosseinalizadeh","year":"2026","unstructured":"Hosseinalizadeh, H. et al. Nanovaccines for lung cancer: platforms, mechanistic insights, and translational challenges. Chin. Med. J. Pulm. Crit. Care Med. 4, 1\u201318 (2026).","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"2982_CR495","doi-asserted-by":"crossref","unstructured":"Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol. 43, 122\u2013134 (2025).","DOI":"10.1038\/s41587-024-02490-y"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02982-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02982-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02982-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:02:46Z","timestamp":1788217366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02982-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":495,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2982"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02982-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"358"}}